US759A
(en)
|
|
1838-05-30 |
|
Reacting watek-wheels |
US5516A
(en)
|
|
1848-04-18 |
|
Combining lantebns and lamps |
US1015498A
(en)
|
1911-03-01 |
1912-01-23 |
Edward L Kraus |
Folding-desk blackboard.
|
NL181407B
(nl)
|
1952-09-20 |
|
Merck & Co Inc |
Verbetering van een werkwijze ter bereiding van een farmaceutisch preparaat met antibacteriele werking, dat een combinatie van een verbinding van het 3-fluor-d-alaninetype en een cycloserineverbinding bevat.
|
GB1039113A
(en)
|
1964-08-06 |
1966-08-17 |
Ucb Sa |
New n-substituted lactams
|
GB1309692A
(en)
|
1970-02-13 |
1973-03-14 |
Ucb Sa |
N-substituted lactams
|
US3539573A
(en)
|
1967-03-22 |
1970-11-10 |
Jean Schmutz |
11-basic substituted dibenzodiazepines and dibenzothiazepines
|
JP2000319257A
(ja)
|
1969-01-06 |
2000-11-21 |
Eisai Co Ltd |
1−ベンジル−4−[(5,6−ジメトキシ−2−フルオロ−1−インダノン)−2−イル]メチルピペリジン
|
US3953603A
(en)
|
1973-11-05 |
1976-04-27 |
Eli Lilly And Company |
Hexahydro-dibenzo[b,d,]pyran-9-ones as psychotropic, particularly anti-depressant drugs
|
US4018895A
(en)
|
1974-01-10 |
1977-04-19 |
Eli Lilly And Company |
Aryloxyphenylpropylamines in treating depression
|
IT1045043B
(it)
|
1975-08-13 |
1980-04-21 |
Isf Spa |
Derivati pirrolidinici
|
NL7605526A
(nl)
|
1976-05-24 |
1977-11-28 |
Akzo Nv |
Nieuwe tetracyclische derivaten.
|
IT1075280B
(it)
|
1977-02-11 |
1985-04-22 |
Isf Spa |
Procedimento per la preparazione di derivati pirrolidinici
|
BE864269A
(fr)
|
1977-03-03 |
1978-06-16 |
Parke Davis & Co |
Nouveaux n-(aminoalkyl substitue)-2-oxo-1-pyrrolidine-acetamides et procedes pour les produire
|
JPS54130587A
(en)
|
1978-03-30 |
1979-10-09 |
Otsuka Pharmaceut Co Ltd |
Carbostyryl derivative
|
ATE27T1
(de)
|
1978-05-08 |
1981-04-15 |
Ucb Sa |
Lactam-n-essigsaeuren und ihre amide, verfahren zu ihrer herstellung und heilmittel, die sie enthalten
|
US4654370A
(en)
|
1979-03-12 |
1987-03-31 |
Abbott Laboratories |
Glyceryl valproates
|
US4431649A
(en)
|
1979-07-30 |
1984-02-14 |
Pfizer Inc. |
Hexahydro-trans- and tetrahydropyridoindole neuroleptic agents
|
US4352807A
(en)
|
1979-07-30 |
1982-10-05 |
Pfizer Inc. |
Hexahydro-trans-pyridoindole neuroleptic agents
|
US4337250A
(en)
|
1979-07-30 |
1982-06-29 |
Pfizer Inc. |
Hexahydro-trans- and tetrahydropyridoindole neuroleptic agents
|
US4465683A
(en)
|
1979-09-14 |
1984-08-14 |
Mead Johnson & Company |
Anti-psychotic agents
|
US4254124A
(en)
|
1979-09-24 |
1981-03-03 |
Mead Johnson & Company |
Antidepressant agent
|
US4372960A
(en)
|
1980-12-12 |
1983-02-08 |
Warner-Lambert Company |
Quaternary derivatives of N-(substituted-aminoalkyl)-2-oxo-1-pyrrolidine-acetamides as cognition activators
|
US4427679A
(en)
|
1981-01-16 |
1984-01-24 |
Pfizer Inc. |
Hexahydro-trans- and tetrahydropyridoindole neuroleptic agents
|
FR2515179A1
(fr)
|
1981-07-24 |
1983-04-29 |
Hoffmann La Roche |
Derives de pyrrolidine, leur procede de preparation, les intermediaires pour leur synthese et leur application therapeutique
|
US4415085A
(en)
|
1981-12-21 |
1983-11-15 |
Eli Lilly And Company |
Dry pharmaceutical system
|
GR81301B
(fr)
|
1982-09-07 |
1984-12-11 |
Lilly Co Eli |
|
PT77267B
(en)
|
1982-09-07 |
1986-03-21 |
Lilly Co Eli |
Improved process for preparing novel octahydrobenz <f> isoquinolines or compounds relating thereto
|
US4879391A
(en)
|
1982-09-20 |
1989-11-07 |
Pfizer Inc. |
1-Phenyl-2(1H,3H)-indolone psychotherapeutic agents
|
US4977178A
(en)
|
1982-09-20 |
1990-12-11 |
Pfizer Inc. |
Method of treating anxiety and depression with 1-phenyl-2(1H,3H)-indolone psycho-therapeutic agents
|
US4476307A
(en)
|
1982-09-20 |
1984-10-09 |
Pfizer Inc. |
Heteroylidene indolone compounds
|
US4495187A
(en)
|
1982-10-18 |
1985-01-22 |
Pfizer Inc. |
Method of using [1,2,4]triazolo[4,3-a]quinoxaline-4-amine derivatives as antidepressant and antifatigue agents
|
IL67623A
(en)
|
1983-01-05 |
1984-09-30 |
Teva Pharma |
1'-ethoxycarbonyloxyethyl ester of valproic acid,its preparation and pharmaceutical compositions containing it
|
IL72381A
(en)
|
1983-07-20 |
1988-03-31 |
Sanofi Sa |
Pharmaceutical composition based on valproic acid
|
US4547501A
(en)
|
1983-09-02 |
1985-10-15 |
Pfizer Inc. |
Method of using [1,2,4]triazolo[4,3-a]quinoxaline-4-amine derivatives as antidepressant and antifatigue agents
|
US4599339A
(en)
|
1983-09-26 |
1986-07-08 |
Eli Lilly And Company |
Use of pyrimido[4,5-g]quinolines in treating parkinsonism
|
US4558070A
(en)
|
1983-10-26 |
1985-12-10 |
Abbott Laboratories |
Acid salts of valproic acid
|
US4605655A
(en)
|
1984-03-06 |
1986-08-12 |
Bristol-Myers Company |
Antipsychotic 1-fluorophenylbutyl-4-(2-pyrimidinyl)piperazine derivatives
|
GB8412357D0
(en)
|
1984-05-15 |
1984-06-20 |
Ucb Sa |
Pharmaceutical composition
|
GB8412358D0
(en)
|
1984-05-15 |
1984-06-20 |
Ucb Sa |
Pharmaceutical composition
|
US4668687A
(en)
|
1984-07-23 |
1987-05-26 |
Bristol-Myers Company |
Psychogeriatric 1-(2-pyrimidinyl)piperazinyl derivatives of 1-pyrrolidin-2-ones
|
US4593037A
(en)
|
1984-07-26 |
1986-06-03 |
Pfizer Inc. |
1,3-disubstituted piperidine compounds as neuroleptic agents
|
US4619930A
(en)
|
1985-01-16 |
1986-10-28 |
Bristol-Myers Company |
Antipsychotic cyclic imide derivatives of 2-(4-butylpiperazin-1-yl)pyridines, compositions and use
|
US4913906B1
(en)
|
1985-02-28 |
2000-06-06 |
Yissum Res Dev Co |
Controlled release dosage form of valproic acid
|
IL74497A
(en)
|
1985-03-05 |
1990-02-09 |
Proterra Ag |
Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
|
US4804663A
(en)
|
1985-03-27 |
1989-02-14 |
Janssen Pharmaceutica N.V. |
3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
|
IE58370B1
(en)
|
1985-04-10 |
1993-09-08 |
Lundbeck & Co As H |
Indole derivatives
|
US4656173A
(en)
|
1985-04-24 |
1987-04-07 |
Bristol-Myers Company |
Antipsychotic benzisothiazole S-oxide compound
|
US4677104A
(en)
|
1985-05-06 |
1987-06-30 |
Bristol-Myers Company |
Antipsychotic fused-ring pyridinylpiperazine derivatives
|
JPS6222785A
(ja)
|
1985-07-23 |
1987-01-30 |
Sanwa Kagaku Kenkyusho:Kk |
新規な2−オキソピロリジン化合物及びその塩、その製法並びにこれらを有効成分とする脳機能障害の予防及び治療剤
|
US4663318A
(en)
|
1986-01-15 |
1987-05-05 |
Bonnie Davis |
Method of treating Alzheimer's disease
|
GB8607684D0
(en)
|
1986-03-27 |
1986-04-30 |
Ici America Inc |
Thiazepine compounds
|
IT1190133B
(it)
|
1986-06-19 |
1988-02-10 |
Chiesi Farma Spa |
Derivati di acido valproico e di acido (e)-2-valproenoico,procedimento per la loro preparazione e relative composizioni farmaceutiche
|
US4757073A
(en)
|
1986-09-30 |
1988-07-12 |
Bristol-Myers Company |
Antipsychotic cyclic imide derivatives of 2-(4-butylipiperazin-1-yl) pyridines, compositions and use
|
US4816456A
(en)
|
1986-10-01 |
1989-03-28 |
Summers William K |
Administration of monoamine acridines in cholinergic neuronal deficit states
|
DD263531A5
(de)
|
1986-10-21 |
1989-01-04 |
������@���Kk�� |
Verfahren zur herstellung von verbrueckten bicyclischen imidverbindungen
|
MX174210B
(es)
|
1987-02-17 |
1994-04-28 |
Pfizer |
Procedimiento para la preparacion de compuestos arilpiperazinil-alquilenfenil-p-heterociclicos
|
MX173362B
(es)
|
1987-03-02 |
1994-02-23 |
Pfizer |
Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
|
US4771053A
(en)
|
1987-03-02 |
1988-09-13 |
Bristol-Myers Company |
Method for alleviation of primary depressive disorders
|
NL195004C
(nl)
|
1987-03-04 |
2003-11-04 |
Novartis Ag |
Fenylcarbamaat bevattend farmaceutisch preparaat.
|
NZ223875A
(en)
|
1987-03-17 |
1991-01-29 |
Hoechst Roussel Pharma |
9-aminotetrahydroacridines and related homologues and pharmaceutical compositions
|
DE3709230A1
(de)
|
1987-03-20 |
1988-10-06 |
Desitin Arzneimittel Gmbh |
Neues calciumsalz der valproinsaeure
|
IT1225462B
(it)
|
1987-04-03 |
1990-11-14 |
Mediolanum Farmaceutici Srl |
Sali organici di derivati della fisostigmina
|
US4784998A
(en)
|
1987-04-06 |
1988-11-15 |
Bristol-Myers Company |
1,3,4-oxadiazole pyschotropic compounds
|
US5002955A
(en)
|
1987-04-23 |
1991-03-26 |
Hoechst-Roussel Pharmaceuticals Inc. |
Fused heteroalkylene quinolinamines and use as cholinergic agents
|
KR100195399B1
(ko)
|
1987-05-04 |
1999-06-15 |
보니데이비스 |
알쯔하이머 병 치료용 의약
|
US5187165A
(en)
|
1987-05-15 |
1993-02-16 |
Hoechst-Roussel Pharmaceuticals Inc. |
Memory enhancing and analgesic 1,2,3a,8,8a-hexahydro-3a,8(and 1,3a,8)-di(and tri)methylpyrrolo[2,3-b]indoles
|
US4931447A
(en)
|
1987-06-15 |
1990-06-05 |
Eli Lilly And Company |
Cycloalkylamides of (8β)-1-alkyl-6-(substituted) ergolines
|
FI95572C
(fi)
|
1987-06-22 |
1996-02-26 |
Eisai Co Ltd |
Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
|
JPS6422883A
(en)
|
1987-07-17 |
1989-01-25 |
Sanwa Kagaku Kenkyusho Co |
1-pyrrolidine acetamide derivative, its salt, production thereof and prophylactic and remedial agent for cereral dysfunction containing said derivative and salt as active ingredient
|
DE3773926D1
(de)
|
1987-07-22 |
1991-11-21 |
Farvalsa Ag |
Feuchtigkeitsstabile feste valproinsaeure-zubereitung und verfahren zu ihrer herstellung.
|
IL87674A
(en)
|
1987-09-08 |
1993-08-18 |
Lilly Co Eli |
Azabicycloalkyl esters and amides of heterocyclic acids, their preparation and pharmaceutical compositions containing them
|
US5364863A
(en)
|
1987-09-08 |
1994-11-15 |
Eli Lilly And Company |
Specific 5-HT3 antagonists
|
US4880930A
(en)
|
1987-11-30 |
1989-11-14 |
New James S |
Psychotropic acyclic amide derivatives
|
US4891375A
(en)
|
1988-01-13 |
1990-01-02 |
Pfizer Inc. |
Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds
|
US4883795A
(en)
|
1988-01-22 |
1989-11-28 |
Pfizer Inc. |
Piperazinyl-heterocyclic compounds
|
US4831031A
(en)
|
1988-01-22 |
1989-05-16 |
Pfizer Inc. |
Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
|
US5001130A
(en)
|
1988-02-18 |
1991-03-19 |
Bristol-Myers Company |
Psychotropic heterobicycloalkylpiperazine derivatives
|
US5238959A
(en)
|
1988-04-08 |
1993-08-24 |
Eli Lilly And Company |
3-phenyloxy-3-phenyl propanamines
|
US5242911A
(en)
|
1988-06-17 |
1993-09-07 |
Pfizer Inc. |
Bridged bicyclic imides as anxiolytics and antidepressants
|
HUT61760A
(en)
|
1988-09-16 |
1993-03-01 |
Pfizer |
Process for producing bridged, bicyclic imides comprising 4-/4-(3-benzisothiazolyl)-1-piperazinyl/-butyl group and pharmaceutical compositions comprising such compounds
|
US5006528A
(en)
|
1988-10-31 |
1991-04-09 |
Otsuka Pharmaceutical Co., Ltd. |
Carbostyril derivatives
|
US5158952A
(en)
|
1988-11-07 |
1992-10-27 |
Janssen Pharmaceutica N.V. |
3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
|
CA2000786C
(fr)
|
1988-11-07 |
1999-01-26 |
Cornelus G. M. Janssen |
3-piperidinyl-1,2-benzisoxazoles
|
US5254556A
(en)
|
1988-11-07 |
1993-10-19 |
Janssen Pharmaceutica N.V. |
3-piperidinyl-1,2-benzisoxazoles
|
MX18467A
(es)
|
1988-11-23 |
1993-07-01 |
Pfizer |
Agentes terapeuticos de quinuclidinas
|
US5153206A
(en)
|
1988-12-02 |
1992-10-06 |
Pfizer Inc. |
Arylpiperidine derivatives
|
US4950658A
(en)
|
1988-12-06 |
1990-08-21 |
Board Of Trustees Of Southern Illinois Univ. |
Method of medical treatment of Alzheimer's disease
|
NZ232112A
(en)
|
1989-01-17 |
1992-07-28 |
Hoffmann La Roche |
((5-oxo-2-pyrrolidinyl)methyl)cyclohexaneacetamides, intermediates therefor and pharmaceutical compositions
|
MX19185A
(es)
|
1989-01-20 |
1993-12-01 |
Pfizer |
Procedimiento para preparar 3-(1,2,5,6-tretrahidropiridil)-pirrolopiridinas.
|
FR2643556B1
(fr)
|
1989-02-27 |
1993-03-05 |
Sanofi Sa |
Composition pharmaceutique a liberation prolongee d'acide valproique
|
US4981870A
(en)
|
1989-03-07 |
1991-01-01 |
Pfizer Inc. |
Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
|
US5238945A
(en)
|
1989-04-11 |
1993-08-24 |
H. Lundbeck A/S |
Method of treating psychoses
|
GB8908085D0
(en)
|
1989-04-11 |
1989-05-24 |
Lundbeck & Co As H |
New therapeutic use
|
US4914207A
(en)
|
1989-05-09 |
1990-04-03 |
Pfizer Inc. |
Arylthiazolylimidazoles
|
US4963689A
(en)
|
1989-05-19 |
1990-10-16 |
Pfizer Inc. |
Heterocyclicguanidines as 5HT3 antagonists
|
US5364866A
(en)
|
1989-05-19 |
1994-11-15 |
Hoechst-Roussel Pharmaceuticals, Inc. |
Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
|
DE69021645T2
(de)
|
1989-05-19 |
1996-02-22 |
Hoechst-Roussel Pharmaceuticals Inc., Somerville, N.J. |
N-(aryloxyalkyl)heteroarylpiperidine und -heteroarylpiperazine, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente.
|
US5693668A
(en)
|
1989-06-22 |
1997-12-02 |
Merrell Pharmaceuticals Inc. |
Acetylcholinesterase inhibitors
|
EP0403713A1
(fr)
|
1989-06-22 |
1990-12-27 |
Merrell Dow Pharmaceuticals Inc. |
Inhibiteurs d'acétylcholinestérase
|
WO1991000863A1
(fr)
|
1989-07-07 |
1991-01-24 |
Pfizer Inc. |
Agents antipsychotiques a base de piperazine d'heteroaryle
|
US5350747A
(en)
|
1989-07-07 |
1994-09-27 |
Pfizer Inc |
Heteroaryl piperazine antipsychotic agents
|
IT1231477B
(it)
|
1989-07-12 |
1991-12-07 |
Sigma Tau Ind Farmaceuti |
(pirrolidin-2-one-1-il) acetammidi quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti
|
US4956368A
(en)
|
1989-07-24 |
1990-09-11 |
Bristol-Myers Company |
Metabolites and prodrug formulations of 8-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dione
|
US5006525A
(en)
|
1989-07-24 |
1991-04-09 |
Eli Lilly And Company |
Dopamine agonists method
|
US4999430A
(en)
|
1989-07-31 |
1991-03-12 |
Warner-Lambert Company |
Derivatives of 1,2,3,4-tetrahydro-9-acrisinamine
|
DE3927049A1
(de)
|
1989-08-16 |
1991-02-21 |
Sandoz Ag |
Halogenalkyl-phenyl-ketone und deren hydrate, ihre herstellung und verwendung
|
WO1991003467A1
(fr)
|
1989-08-30 |
1991-03-21 |
Pfizer Inc. |
Carbamates benzazabicycliques utilises comme nouveaux inhibiteurs de cholinesterase
|
US4914102A
(en)
|
1989-09-28 |
1990-04-03 |
Hoechst Roussel Pharmaceuticals, Inc. |
N-aminocarbamates related to physostigmine, pharmacentical compositions and use
|
US5011841B1
(en)
|
1989-11-14 |
1994-09-06 |
Pfizer |
Treatment of depression
|
US5232929A
(en)
|
1990-11-28 |
1993-08-03 |
Pfizer Inc. |
3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
|
UA41251C2
(uk)
|
1990-01-04 |
2001-09-17 |
Пфайзер, Інк. |
Гідровані азотвмісні гетероциклічні сполуки, похідні піперидину, фармацевтична композиція та спосіб пригнічення активності речовини р в організмі
|
NZ237241A
(en)
|
1990-03-02 |
1993-11-25 |
Pharmetrix Corp |
Method for increasing the storage stability of physostigmine
|
US5043341A
(en)
|
1990-04-11 |
1991-08-27 |
Eli Lilly And Company |
N-(2-hydroxycyclopentyl)-1-isopropyl-6-methylergoline-8-carboxamides
|
US5229382A
(en)
|
1990-04-25 |
1993-07-20 |
Lilly Industries Limited |
2-methyl-thieno-benzodiazepine
|
DE69105131T2
(de)
|
1990-06-01 |
1995-03-23 |
Pfizer |
3-amino-2-arylchinuclidine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
|
JP2807577B2
(ja)
|
1990-06-15 |
1998-10-08 |
エーザイ株式会社 |
環状アミド誘導体
|
JP2800953B2
(ja)
|
1990-07-06 |
1998-09-21 |
住友製薬株式会社 |
新規なイミド誘導体
|
US5399565A
(en)
|
1990-07-17 |
1995-03-21 |
Eli Lilly And Company |
Pyrazolidinone CCK and gastrin antagonists and pharmaceutical formulations therof
|
DE69106365T2
(de)
|
1990-07-23 |
1995-05-04 |
Pfizer |
Chinuclidinderivate.
|
US5102891A
(en)
|
1990-07-23 |
1992-04-07 |
Hoechst-Roussel Pharmaceuticals Inc. |
1-(substituted pyridinylamino)-1H-indol-5-yl substituted carbamates
|
US5264442A
(en)
|
1990-08-13 |
1993-11-23 |
Hoechst-Roussel Pharmaceuticals Incorporated |
Carbamoyl-1-(pyridinylalkyl)-1H-indoles, indolines and related analogs
|
TW200462B
(fr)
|
1990-09-27 |
1993-02-21 |
Hoechst Roussel Pharma |
|
EP0550635B1
(fr)
|
1990-09-28 |
1995-04-19 |
Pfizer Inc. |
Analogues cycliques d'heterocycles non aromatiques contenant de l'azote
|
US5578612A
(en)
|
1990-10-15 |
1996-11-26 |
Pfizer Inc. |
Indole derivatives
|
US5559129A
(en)
|
1990-10-15 |
1996-09-24 |
Pfizer Inc |
Indole derivatives
|
CA2091562C
(fr)
|
1990-10-15 |
2001-03-27 |
John Eugene Macor |
Derives de l'indole
|
US5190951A
(en)
|
1990-10-19 |
1993-03-02 |
Ss Pharmaceutical Co., Ltd. |
Quinoline derivatives
|
US5147881A
(en)
|
1990-11-14 |
1992-09-15 |
Pfizer Inc |
4-(1,2-benzisoxazolyl)piperidine antipsychotic agents
|
JP2965675B2
(ja)
|
1990-11-21 |
1999-10-18 |
エーザイ株式会社 |
(―)―1―ベンジル―4―〔(5,6―ジメトキシ―1―インダノン)―2―イル〕メチルピペリジンの製造方法
|
TW197435B
(fr)
|
1990-11-22 |
1993-01-01 |
Takeda Pharm Industry Co Ltd |
|
JPH04327532A
(ja)
|
1991-01-31 |
1992-11-17 |
Bristol Myers Squibb Co |
活動過剰を伴う注意力欠乏疾患の治療に使用する医薬製剤
|
US5668117A
(en)
|
1991-02-22 |
1997-09-16 |
Shapiro; Howard K. |
Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
|
US5157034A
(en)
|
1991-02-27 |
1992-10-20 |
Pfizer Inc. |
Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines
|
CA2105302C
(fr)
|
1991-03-01 |
1996-11-12 |
Pfizer Limited |
Derives de 1-azabicyclo¬3.2.2|nonan-3-amine
|
US5334720A
(en)
|
1991-03-07 |
1994-08-02 |
Fisons Corporation |
Diphenyl-1-(aminoalkyl)-2-piperidinone and -2-pyrrolidinone derivatives having anticonvulsant properties
|
JP2659107B2
(ja)
|
1991-03-28 |
1997-09-30 |
エーザイ株式会社 |
複素環式―環式アミン誘導体
|
US5750542A
(en)
|
1993-09-28 |
1998-05-12 |
Pfizer |
Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
|
US5817656A
(en)
|
1991-04-23 |
1998-10-06 |
Eli Lilly And Company |
Mental disorders
|
US5817655A
(en)
|
1991-04-23 |
1998-10-06 |
Eli Lilly And Company |
Methods of treatment using a thieno-benzodiazepine
|
US5627178A
(en)
|
1991-04-23 |
1997-05-06 |
Lilly Industries Limited |
2-methyl-thieno-benzodiazepine
|
US5104880A
(en)
|
1991-05-01 |
1992-04-14 |
Mayo Foundation For Medical Education And Research |
Huperzine a analogs as acetylcholinesterase inhibitors
|
SK279285B6
(sk)
|
1991-05-02 |
1998-09-09 |
Daiichi Pharmaceutical Co. |
Použitie n-(2,6-dimetylfenyl)-2-(2-oxo-1-pyrolidin
|
US5716965A
(en)
|
1991-05-22 |
1998-02-10 |
Pfizer Inc. |
Substituted 3-aminoquinuclidines
|
FR2677019B1
(fr)
|
1991-05-27 |
1994-11-25 |
Pf Medicament |
Nouvelles piperidines disubstituees-1,4, leur preparation et leur application en therapeutique.
|
UA27776C2
(uk)
|
1991-05-31 |
2000-10-16 |
Пфайзер Інк. |
Похідні хінуклідину та їх фармацевтично прийнятні солі, що є антагоністами речовини р у ссавців, фармацевтична композиція, що має антагоністичну дію на речовину р у ссавців
|
US5106856A
(en)
|
1991-06-07 |
1992-04-21 |
Hoechst-Roussel Pharmaceuticals Inc. |
[(Arylalkylpiperidin-4-yl)methyl]-2a,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-ones and related compounds
|
DE69213451T2
(de)
|
1991-06-20 |
1997-01-09 |
Pfizer Inc., New York |
Fluoralkoxybenzylaminoderivate stickstoffhaltiger heterocyclen
|
TW202432B
(fr)
|
1991-06-21 |
1993-03-21 |
Pfizer |
|
FR2679555B1
(fr)
|
1991-07-25 |
1993-11-19 |
Fabre Medicament Pierre |
Nouveaux derives de l'uree, leur preparation et leur application en therapeutique.
|
EP0597956A1
(fr)
|
1991-07-29 |
1994-05-25 |
Warner-Lambert Company |
Derives de quinazoline utilises en tant qu'inhibiteurs d'acetylcholinesterase
|
IT1251166B
(it)
|
1991-08-09 |
1995-05-04 |
Chiesi Farma Spa |
Derivati di geneserina,loro preparazione e composizioni farmaceutiche che li contengono
|
JP2535134B2
(ja)
|
1991-09-16 |
1996-09-18 |
ファイザー・インコーポレーテッド |
縮合三環式窒素含有複素環
|
US5161533A
(en)
|
1991-09-19 |
1992-11-10 |
Xomed-Treace Inc. |
Break-apart needle electrode system for monitoring facial EMG
|
US5246947A
(en)
|
1991-09-23 |
1993-09-21 |
Hoechst-Roussel Pharmaceuticals Incorporated |
Substituted pyridinylamino-1,2-benzisothiazoles and their use for treating depression
|
JPH08827B2
(ja)
|
1991-09-25 |
1996-01-10 |
フアイザー・インコーポレイテツド |
精神弛緩剤の2−置換パーヒドロ−1H−ピリド[1,2−aピラジン
|
US5231093A
(en)
|
1991-10-01 |
1993-07-27 |
Hoechst-Roussel Pharmaceuticals Incorporated |
Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
|
TW263504B
(fr)
|
1991-10-03 |
1995-11-21 |
Pfizer |
|
EP0537993A1
(fr)
|
1991-10-17 |
1993-04-21 |
Eli Lilly And Company |
Activité nicotinique d'une série d'arécolines et d'isoarécolines
|
US5710168A
(en)
|
1991-10-23 |
1998-01-20 |
Pfizer Inc. |
2-piperidino-1-alkanol derivatives as neuroprotective agents
|
DK0613458T3
(da)
|
1991-11-12 |
1998-02-09 |
Pfizer |
Acykliske ethylendiaminderivater som substans P receptorantagonister
|
WO1993011106A1
(fr)
|
1991-11-25 |
1993-06-10 |
Pfizer, Inc. |
Derives d'indole
|
US5137894A
(en)
|
1991-12-05 |
1992-08-11 |
New James S |
4-(4-Piperidinyl-thieno[3,2-c]pyridine derivatives of n-alkylglutarimides
|
ES2042384B1
(es)
|
1991-12-26 |
1994-06-01 |
Boehringer Ingelheim Espana |
Procedimiento para obtener derivados bis-piridinicos.
|
EP0619814A1
(fr)
|
1991-12-31 |
1994-10-19 |
Fujisawa Pharmaceutical Co., Ltd. |
Derives d'oxadiazole a effet inhibiteur de l'acetylcholinesterase et agoniste muscarinique
|
JPH07505145A
(ja)
|
1992-02-25 |
1995-06-08 |
ワーナー−ランバート・コンパニー |
細胞保護組成物およびその製法および使用法
|
TW288010B
(fr)
|
1992-03-05 |
1996-10-11 |
Pfizer |
|
US5569662A
(en)
|
1992-03-23 |
1996-10-29 |
Pfizer Inc. |
Quinuclidine derivatives as substance P antagonists
|
CZ281763B6
(cs)
|
1992-04-07 |
1997-01-15 |
Pfizer Inc. |
Indolové deriváty představující 5-HT1 agonisty, způsob jejich přípravy, farmaceutické prostředky obsahující tyto látky, jejich použití a meziprodukty postupu přípravy
|
US6380233B1
(en)
|
1992-04-07 |
2002-04-30 |
Pfizer Inc |
Indole derivatives as 5-HT1 agonists
|
ATE148465T1
(de)
|
1992-04-10 |
1997-02-15 |
Pfizer |
Acylaminoindolderivate als 5-ht1 agonisten
|
US5439930A
(en)
|
1992-04-14 |
1995-08-08 |
Russian-American Institute For New Drug Development |
Biologically active n-acylprolydipeptides having antiamnestic, antihypoxic and anorexigenic effects
|
US5256664A
(en)
|
1992-04-28 |
1993-10-26 |
Bristol-Myers Squibb Company |
Antidepressant 3-halophenylpiperazinylpropyl derivatives of substituted triazolones and triazoldiones
|
US20050256162A1
(en)
|
1992-05-05 |
2005-11-17 |
Pfizer Inc |
Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
|
US5498614A
(en)
|
1992-05-18 |
1996-03-12 |
Pfizer Inc. |
Bridged aza-bicyclic derivatives as substance P antagonist
|
IT1254996B
(it)
|
1992-06-25 |
1995-10-11 |
Mediolanum Farmaceutici Srl |
Esteri amminoalchilcarbammici dell'eserolina atti all'impiego come anticolinesterasici e relativo procedimento di preparazione
|
US5688804A
(en)
|
1992-08-04 |
1997-11-18 |
Pfizer Inc. |
3-Benzylamino-2-phenyl-piperidine derivatives as substance P receptor antagonists
|
ES2164072T3
(es)
|
1992-08-19 |
2002-02-16 |
Pfizer |
Heterociclos no aromaticos que contienen nitrogeno sustituidos con bencilamino.
|
US5312925A
(en)
|
1992-09-01 |
1994-05-17 |
Pfizer Inc. |
Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
|
US5440023A
(en)
|
1992-09-18 |
1995-08-08 |
Beckman Instruments, Inc. |
Method for making valproic acid derivatives
|
US5604241A
(en)
|
1992-10-21 |
1997-02-18 |
Pfizer Inc. |
Substituted benzylaminoquinuclidines as substance P antagonists
|
US5837711A
(en)
|
1992-10-28 |
1998-11-17 |
Pfizer Inc. |
Substituted quinuclidines as substance P antagonists
|
TW251284B
(fr)
|
1992-11-02 |
1995-07-11 |
Pfizer |
|
US5498610A
(en)
|
1992-11-06 |
1996-03-12 |
Pfizer Inc. |
Neuroprotective indolone and related derivatives
|
CA2149242C
(fr)
|
1992-11-12 |
1998-08-04 |
Fumitaka Ito |
Derive de la quinuclidine pour le traitement de troubles inflammatoires et gastro-intestinaux
|
US6369074B1
(en)
|
1992-12-10 |
2002-04-09 |
Pfizer Inc. |
Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists
|
ES2147759T3
(es)
|
1992-12-10 |
2000-10-01 |
Pfizer |
Heterociclos no aromaticos sustituidos con aminometileno y uso como antagonistas de la sustancia p.
|
US5352459A
(en)
|
1992-12-16 |
1994-10-04 |
Sterling Winthrop Inc. |
Use of purified surface modifiers to prevent particle aggregation during sterilization
|
TW444018B
(en)
|
1992-12-17 |
2001-07-01 |
Pfizer |
Pyrazolopyrimidines
|
PL176526B1
(pl)
|
1992-12-17 |
1999-06-30 |
Pfizer |
Pirolopirymidyny jako związki o działaniu antagonistów czynnika uwalniającego kortykotropinę
|
EP0611769A1
(fr)
|
1993-02-16 |
1994-08-24 |
Merrell Dow Pharmaceuticals Inc. |
Inhibiteurs d'acétylcholinerase silylés
|
WO1994020476A1
(fr)
|
1993-03-02 |
1994-09-15 |
Fujisawa Pharmaceutical Co., Ltd. |
Nouveau compose heterocyclique
|
AU6226494A
(en)
|
1993-03-04 |
1994-09-26 |
Pfizer Inc. |
Spiroazacyclic derivatives as substance p antagonists
|
WO1994021619A1
(fr)
|
1993-03-16 |
1994-09-29 |
Pfizer Inc. |
Derives de naphtalene
|
IL109646A0
(en)
|
1993-05-19 |
1994-08-26 |
Pfizer |
Heteroatom substituted alkyl benzylamino-quinuclidines
|
EP0627400A1
(fr)
|
1993-06-04 |
1994-12-07 |
Merrell Dow Pharmaceuticals Inc. |
Inhibiteurs aromatiques d'acétylcholinesterase
|
SE9302080D0
(sv)
|
1993-06-16 |
1993-06-16 |
Ab Astra |
New compounds
|
CA2167198C
(fr)
|
1993-07-15 |
1999-03-16 |
Kunio Satake |
Benzylaminoquinuclidines
|
CZ59996A3
(en)
|
1993-08-31 |
1996-06-12 |
Pfizer |
5-arylindole derivatives per se and for treating diseases, intermediates for their preparation and pharmaceutical compositions based thereon
|
AU7082194A
(en)
|
1993-09-17 |
1995-04-03 |
Pfizer Inc. |
Heteroarylamino and heteroarylsulfonamido substituted 3-benzylaminomethyl piperidines and related compounds
|
US6083943A
(en)
|
1993-09-17 |
2000-07-04 |
Pfizer Inc |
Substituted azaheterocyclecarboxylic acid
|
GB9319732D0
(en)
|
1993-09-24 |
1993-11-10 |
Ucb Sa |
Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety
|
US5468733A
(en)
|
1993-09-30 |
1995-11-21 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
BR9408450A
(pt)
|
1993-12-29 |
1997-08-05 |
Pfizer |
Antagonistas da neuroquinina diazabiciclicos
|
AU692530B2
(en)
|
1994-03-02 |
1998-06-11 |
Merck Sharp & Dohme B.V. |
Sublingual or buccal pharmaceutical composition
|
ATE271553T1
(de)
|
1994-04-29 |
2004-08-15 |
Pfizer |
Neue cyclische und acyclische amide zur erhöhung der neurotransmitter ausschüttung
|
DK0765327T3
(da)
|
1994-06-16 |
1999-11-29 |
Pfizer |
Pyrazolo- og pyrrolopyridiner
|
US5744476A
(en)
|
1994-06-27 |
1998-04-28 |
Interneuron Pharmaceuticals, Inc. |
Dopamine D1 agonists for the treatment of dementia
|
WO1996000720A1
(fr)
|
1994-06-29 |
1996-01-11 |
Pfizer Inc. |
Derives d'aryle et heteroaryle alkoxynaphtalene
|
MX9700693A
(es)
|
1994-07-26 |
1997-04-30 |
Pfizer |
Derivados del 4-indol.
|
CA2197451C
(fr)
|
1994-08-18 |
2001-01-23 |
Bertrand L. Chenard |
Derives de 3-(piperidinyl-1)chromane-4,7-diol et de 1-(4-hydrophenyl)-2-(piperidinyl-1)alcanol, agents neuroprotecteurs
|
US5597826A
(en)
|
1994-09-14 |
1997-01-28 |
Pfizer Inc. |
Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
|
US5627200A
(en)
|
1994-09-26 |
1997-05-06 |
Pfizer Inc |
β3 -Adrenoceptor agonists and antagonists for the treatment of intestinal motility disorders, depression, prostate disease and dyslipidemia
|
US5731307A
(en)
|
1994-09-30 |
1998-03-24 |
Pfizer, Inc. |
Neuroleptic 2,7-disubtituted perhydro-1h-pyrido 1, 2-A!pyrazines
|
US5516759A
(en)
|
1994-12-08 |
1996-05-14 |
Tap Holdings Inc. |
LHRH antagonists having lactam groups at the N-terminus
|
US5658590A
(en)
|
1995-01-11 |
1997-08-19 |
Eli Lilly And Company |
Treatment of attention-deficit/hyperactivity disorder
|
US5741789A
(en)
|
1995-01-17 |
1998-04-21 |
Eli Lilly And Company |
Compounds having effects on serotonin-related systems
|
US5576321A
(en)
|
1995-01-17 |
1996-11-19 |
Eli Lilly And Company |
Compounds having effects on serotonin-related systems
|
AU4918796A
(en)
|
1995-02-10 |
1996-08-27 |
Eli Lilly And Company |
Methods of treating or preventing psychiatric disorders
|
CR5278A
(es)
|
1995-03-24 |
1996-07-04 |
Lilly Co Eli |
Formulacion oral de 2-metil-tieno-benzodiacepina
|
EG23659A
(en)
|
1995-03-24 |
2007-03-26 |
Lilly Co Eli |
Process and crystal forms of methyl-thieno-benzodiazepine
|
JPH11503757A
(ja)
|
1995-04-18 |
1999-03-30 |
イーライ・リリー・アンド・カンパニー |
5−ht▲下7▼レセプターにおいて生理学的および病理学的機能を生じるエルゴリン化合物の使用方法
|
US5889010A
(en)
|
1995-05-18 |
1999-03-30 |
Pfizer Inc. |
Benzimidazole derivatives having dopaminergic activity
|
US20010023248A1
(en)
|
1995-05-25 |
2001-09-20 |
Howard Harry R. |
Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists
|
US6403599B1
(en)
|
1995-11-08 |
2002-06-11 |
Pfizer Inc |
Corticotropin releasing factor antagonists
|
IL118279A
(en)
|
1995-06-07 |
2006-10-05 |
Abbott Lab |
Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
|
JP3042894B2
(ja)
|
1995-07-07 |
2000-05-22 |
ファイザー製薬株式会社 |
サブスタンスpアンタゴニストとしての置換ベンゾラクタム化合物
|
US5696168A
(en)
|
1995-07-24 |
1997-12-09 |
Eli Lilly And Company |
Treatment of attention-deficit/hyperactivity disorder
|
CZ16798A3
(cs)
|
1995-07-24 |
1998-11-11 |
Eli Lilly And Company |
Použití duloxetinu pro léčbu poruch pozornosti /hyperaktivity a farmaceutický prostředek s jeho obsahem
|
TW340842B
(en)
|
1995-08-24 |
1998-09-21 |
Pfizer |
Substituted benzylaminopiperidine compounds
|
IL115113A
(en)
|
1995-08-31 |
2002-11-10 |
Israel State |
3-carbamoyloxy pyridinium derivatives and pharmaceutical compositions containing them
|
ES2100129B1
(es)
|
1995-10-11 |
1998-02-16 |
Medichem Sa |
Nuevos compuestos aminopiridinicos policiclicos inhibidores de acetilcolinesterasa, procedimiento para su preparacion y su utilizacion.
|
CA2237752C
(fr)
|
1995-11-17 |
2006-05-16 |
Sibia Neurosciences, Inc. |
Nouveaux composes d'aryle substitues utiles comme modulateurs des recepteurs de l'acetylcholine
|
US5783584A
(en)
|
1995-12-11 |
1998-07-21 |
Mayo Foundation For Medical Education And Research |
THA analogs useful as cholinesterase inhibitors
|
ATE223896T1
(de)
|
1995-12-21 |
2002-09-15 |
Pfizer |
3-((5-substituierte benzyl)amino)-2- phenylpiperidine als substance-p-antagonisten
|
US5958921A
(en)
|
1995-12-22 |
1999-09-28 |
Eli Lilly And Company |
Method for treating depression with olanzapine
|
US5625897A
(en)
|
1996-01-11 |
1997-05-06 |
Park; Kelly R. |
Upper torso garment
|
CA2243500A1
(fr)
|
1996-01-22 |
1997-07-24 |
Joseph Wendell Wilson |
Procede combinatoire de preparation d'echantillotheques d'indane substitue
|
GB9606736D0
(en)
|
1996-02-19 |
1996-06-05 |
Shire International Licensing |
Therapeutic method
|
WO1997033577A1
(fr)
|
1996-03-11 |
1997-09-18 |
Eli Lilly And Company |
Methode de traitement des troubles bipolaires
|
EP0906104A4
(fr)
|
1996-03-25 |
2003-12-10 |
Lilly Co Eli |
Procede de traitement de la douleur
|
US6326368B1
(en)
|
1996-03-27 |
2001-12-04 |
Dupont Pharmaceuticals Company |
Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof
|
US6107300A
(en)
|
1996-03-27 |
2000-08-22 |
Dupont Pharmaceuticals |
Arylamino fused pyrimidines
|
SK131498A3
(en)
|
1996-03-29 |
2000-09-12 |
Pfizer |
BENZYL(IDENE)-LACTAM DERIVATIVES, THEIR PREPARATION AND THEIR USEì (54) AS SELECTIVE (ANT)AGONISTS OF 5-HT1A- AND/OR 5-HT1D
|
CN1168719C
(zh)
|
1996-03-29 |
2004-09-29 |
辉瑞大药厂 |
6-苯基吡啶-2-基胺衍生物以及药物组合物和用途
|
BR9708655A
(pt)
|
1996-04-12 |
1999-08-03 |
Hoechst Marion Roussel Inc |
Derivados de isatina como inibidores de acetilcolinesterase e analgésicos
|
TW491847B
(en)
|
1996-05-07 |
2002-06-21 |
Pfizer |
Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
|
AU730856C
(en)
|
1996-05-07 |
2001-11-15 |
Pfizer Inc. |
Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol- 3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1H)- indol-2-one(=ziprasidone),it's preparation and it's use as dopamine D2 antagonist
|
TW487572B
(en)
|
1996-05-20 |
2002-05-21 |
Janssen Pharmaceutica Nv |
Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
|
EP1380298A3
(fr)
|
1996-05-23 |
2004-04-07 |
Bristol-Myers Squibb Pharma Company |
Tétrahydroptéridines et pyridylpipérazines pour le traitement de désordres neurologiques, anoréxie, inflammations
|
US5948437A
(en)
|
1996-05-23 |
1999-09-07 |
Zeneca Limited |
Pharmaceutical compositions using thiazepine
|
ZA973884B
(en)
|
1996-05-23 |
1998-11-06 |
Du Pont Merck Pharma |
Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
|
DE69708968T2
(de)
|
1996-05-28 |
2002-04-25 |
Pfizer |
Arylacrylamidderivate als 5HT1 Agoniste oder Antagoniste
|
AU1153097A
(en)
|
1996-06-07 |
1998-01-05 |
Eisai Co. Ltd. |
Stable polymorphs of donepezil (1-benzyl-4-{(5,6-dimethoxy-1-indanon)-2-yl}methylpiperidine ) hydrochloride and process for production
|
TW513409B
(en)
|
1996-06-07 |
2002-12-11 |
Eisai Co Ltd |
Polymorphs of donepezil hydrochloride
|
US6329396B1
(en)
|
1996-06-10 |
2001-12-11 |
Pfizer Inc. |
Substituted benzylaminopiperidine compounds
|
US5912256A
(en)
|
1996-06-20 |
1999-06-15 |
Eli Lilly And Company |
Compounds having effects on serotonin-related systems
|
CA2180703A1
(fr)
|
1996-07-08 |
1998-01-09 |
Paul Marie Victor Gilis |
Comprime de bromhydrate de galanthamine a dissolution rapide
|
US6191131B1
(en)
|
1997-07-23 |
2001-02-20 |
Dupont Pharmaceuticals Company |
Azolo triazines and pyrimidines
|
US7094782B1
(en)
|
1996-07-24 |
2006-08-22 |
Bristol-Myers Squibb Company |
Azolo triazines and pyrimidines
|
CZ2005613A3
(cs)
|
1996-07-24 |
2017-01-25 |
Bristol-Myers Squibb Pharma Company |
Azolopyrimidiny, jejich použití a farmaceutické kompozice na jejich bázi
|
US6117890A
(en)
|
1996-08-01 |
2000-09-12 |
Eli Lilly And Company |
Method for treating bipolar disorder
|
PT821955E
(pt)
|
1996-08-01 |
2002-07-31 |
Lilly Co Eli |
Uso de 3-(4-hexiloxi-1,2,5-tiadiazol-3-il)-1,2,5,6-tetrahidro-1-metilpiridina (xanomelina) para o tratamento da doenca bipolar
|
US6043258A
(en)
|
1996-08-01 |
2000-03-28 |
Eli Lilly And Company |
Method for treating disruptive behavior disorders with xanomeline
|
MX9706196A
(es)
|
1996-08-14 |
1998-02-28 |
Pfizer |
Compuestos triciclicos de piperidinilamino como antagonistas de la sustancia p.
|
WO1998007431A1
(fr)
|
1996-08-22 |
1998-02-26 |
New York University |
Inhibiteurs de la cholinesterase pour le traitement de la maladie de parkinson
|
ZA977967B
(en)
|
1996-09-23 |
1999-03-04 |
Lilly Co Eli |
Combination therapy for treatment of psychoses
|
HU226167B1
(hu)
|
1996-09-23 |
2008-05-28 |
Lilly Co Eli |
Olanzapin-dihidrát D, elõállítása és az azt tartalmazó gyógyszerkészítmények
|
UA56185C2
(uk)
|
1996-09-30 |
2003-05-15 |
Пфайзер Інк. |
Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
|
US6423708B1
(en)
|
1996-09-30 |
2002-07-23 |
Pfizer Inc |
Aralkyl and aralkylidene heterocyclic lactams and imides
|
IT1285801B1
(it)
|
1996-10-10 |
1998-06-24 |
Sigma Tau Ind Farmaceuti |
Procedimento migliorato per la preparazione dell'acido valproico
|
ES2264169T3
(es)
|
1996-10-30 |
2006-12-16 |
Pfizer Inc. |
Derivados azabiciclicos de piridona fusionada o de citisina, su preparacion y su uso en la terapia de adiccion.
|
WO1998030243A1
(fr)
|
1997-01-08 |
1998-07-16 |
Warner-Lambert Company |
Inhibiteurs d'acetylcholinesterase en combinaison avec des agonistes muscariniques utilises dans le traitement de la maladie d'alzheimer
|
KR100324058B1
(ko)
|
1997-01-29 |
2002-02-16 |
디. 제이. 우드, 스피겔 알렌 제이 |
술포닐 우레아 유도체 및 인터루킨-1 활성 조절에서의 그의 용도
|
US6020335A
(en)
|
1997-02-06 |
2000-02-01 |
Pfizer Inc |
(N-(pyridinylmethyl)-heterocyclic)ylideneamine compounds as nicotinic acetylcholine receptor binding agents
|
NZ337515A
(en)
|
1997-03-03 |
2002-07-26 |
Eisai Co Ltd |
Use of cholinesterase inhibitors to treat disorders of attention
|
GB2323788B
(en)
|
1997-04-02 |
1999-02-17 |
Bristol Myers Squibb Co |
Venting valve for ostomy bag
|
ID22781A
(id)
|
1997-04-04 |
1999-12-09 |
Pfizer Prod Inc |
Turunan-turunan nikotinamida
|
ZA982877B
(en)
|
1997-04-09 |
1999-10-04 |
Lilly Co Eli |
Treatment of central nervous system disorders with selective estrogen receptor modulators.
|
WO1998046226A1
(fr)
|
1997-04-11 |
1998-10-22 |
Eli Lilly And Company |
Traitement de la schizophrenie
|
WO1998046225A1
(fr)
|
1997-04-11 |
1998-10-22 |
Eli Lilly And Company |
Traitement contre la schizophrenie
|
US5910319A
(en)
|
1997-05-29 |
1999-06-08 |
Eli Lilly And Company |
Fluoxetine enteric pellets and methods for their preparation and use
|
US6627755B1
(en)
|
1997-06-09 |
2003-09-30 |
Pfizer Inc |
Quinazolin-4-one AMPA antagonists
|
EP0884310B1
(fr)
|
1997-06-09 |
2005-09-07 |
Pfizer Products Inc. |
Quinazolin-4-ones comme antagonistes de récepteur AMPA
|
US6060479A
(en)
|
1997-06-09 |
2000-05-09 |
Pfizer Inc |
Quinazoline-4-one AMPA antagonists
|
WO1999004778A1
(fr)
|
1997-07-22 |
1999-02-04 |
Eli Lilly And Company |
Composes pharmaceutiques
|
GB9716879D0
(en)
|
1997-08-08 |
1997-10-15 |
Shire Int Licensing Bv |
Treatment of attention deficit disorders
|
WO1999008672A1
(fr)
|
1997-08-15 |
1999-02-25 |
Shire International Licensing Bv |
Utilisateur d'un inhibiteur de cholinesterase pour traiter des maladies liees a l'activite de l'enzyme proteolytique
|
US6479523B1
(en)
|
1997-08-26 |
2002-11-12 |
Emory University |
Pharmacologic drug combination in vagal-induced asystole
|
US6323208B1
(en)
|
1997-09-05 |
2001-11-27 |
Pfizer Inc |
Atropisomers of 2,3-disubstituted-(5.6)-heteroaryl fused-pyrimidin-4-ones
|
IL125951A
(en)
|
1997-09-05 |
2003-09-17 |
Pfizer Prod Inc |
A pharmaceutical composition comprising a piperazinyl-heterocyclic compound for treating tourette's syndrome, obsessive compulsive disorder, chronic motor or vocal tic disorder in a mammal
|
CA2304112A1
(fr)
|
1997-09-23 |
1999-04-01 |
John Harrison Heiligenstein |
Traitement des troubles lies a l'hyperactivite et au deficit de l'attention
|
UA72189C2
(uk)
|
1997-11-17 |
2005-02-15 |
Янссен Фармацевтика Н.В. |
Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
|
ATE260896T1
(de)
|
1997-12-05 |
2004-03-15 |
Eisai Co Ltd |
Donepezil polykristalle und verfharen zu ihrer herstellung
|
IL135315A0
(en)
|
1997-12-16 |
2001-05-20 |
Warner Lambert Co |
4(3)-substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (gabapentin analogues), their preparation and their use in the treatment of neurological disorders
|
IL127497A
(en)
|
1997-12-18 |
2002-07-25 |
Pfizer Prod Inc |
Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
|
NZ505079A
(en)
|
1998-01-28 |
2003-08-29 |
Du Pont Pharm Co |
Pyrazolotriazines and pyrazolopyrimidines useful as corticotropin releasing factor antagonists
|
US6131106A
(en)
|
1998-01-30 |
2000-10-10 |
Sun Microsystems Inc |
System and method for floating-point computation for numbers in delimited floating point representation
|
AU2495399A
(en)
|
1998-02-06 |
1999-08-23 |
Eli Lilly And Company |
Desert hedgehog related nucleic acids and proteins
|
GB9805561D0
(en)
|
1998-03-16 |
1998-05-13 |
Merck Sharp & Dohme |
A combination of therapeutic agents
|
PA8469101A1
(es)
|
1998-04-09 |
2000-09-29 |
Pfizer Prod Inc |
Ligandos azabiciclicos de receptores 5ht1
|
PA8469501A1
(es)
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
|
ATE228119T1
(de)
|
1998-04-15 |
2002-12-15 |
Pfizer Prod Inc |
Heterocyclische carboxamide
|
ES2226284T3
(es)
|
1998-04-16 |
2005-03-16 |
Pfizer Products Inc. |
N-acil y n-aroil-aralquilamidas.
|
AU3891299A
(en)
|
1998-05-21 |
1999-12-06 |
Eli Lilly And Company |
Combination therapy for treatment of depression
|
GT199900060A
(es)
|
1998-05-22 |
2000-10-14 |
|
Polimorfos de un monoclorhidrato de pirazina cristalino y sus composiciones farmacèuticas.
|
US6960577B2
(en)
|
1998-05-22 |
2005-11-01 |
Eli Lilly And Company |
Combination therapy for treatment of refractory depression
|
KR20010043730A
(ko)
|
1998-05-22 |
2001-05-25 |
피터 지. 스트링거 |
치료 불응성 우울증의 치료를 위한 조합 치료법
|
EA003611B1
(ru)
|
1998-05-29 |
2003-06-26 |
Эли Лилли Энд Компани |
Комбинационная терапия для лечения биполярных расстройств
|
US6150366A
(en)
|
1998-06-15 |
2000-11-21 |
Pfizer Inc. |
Ziprasidone formulations
|
US6436914B1
(en)
|
1998-06-30 |
2002-08-20 |
Bristol-Myers Squibb Company |
2-hydroxy-3—(4-hydroxy-3-sulfonamidophenyl)—propylamines useful as beta 3 adrenergic agonists
|
US6312717B1
(en)
|
1998-07-07 |
2001-11-06 |
Bristol-Myers Squibb Company |
Method for treatment of anxiety and depression
|
US6262081B1
(en)
|
1998-07-10 |
2001-07-17 |
Dupont Pharmaceuticals Company |
Composition for and method of treating neurological disorders
|
US6218383B1
(en)
|
1998-08-07 |
2001-04-17 |
Targacept, Inc. |
Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
|
ATE229955T1
(de)
|
1998-08-11 |
2003-01-15 |
Pfizer Prod Inc |
Substituierte 1,8-naphthyridin-4(1h)-one als phosphodiesterase 4-inhibitoren
|
IL125809A
(en)
|
1998-08-17 |
2005-08-31 |
Finetech Lab Ltd |
Process and intermediates for production of donepezil and related compounds
|
IT1304904B1
(it)
|
1998-09-11 |
2001-04-05 |
Eisai Co Ltd |
Derivati anticolinesterasici per il trattamento delle sindromidolorose funzionali e/o organiche
|
HN1999000146A
(es)
|
1998-09-21 |
2000-11-11 |
Pfizer Prod Inc |
Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
|
PL348107A1
(en)
|
1998-10-16 |
2002-05-06 |
Janssen Pharmaceutica Nv |
Therapy for improving cognition
|
US5994352A
(en)
|
1998-11-13 |
1999-11-30 |
Pfizer Inc. |
5-arylindole derivatives
|
US7939522B1
(en)
|
1998-11-23 |
2011-05-10 |
Bonnie M Davis |
Dosage formulations for acetylcholinesterase inhibitors
|
AU1602100A
(en)
|
1998-11-25 |
2000-06-13 |
Warner-Lambert Company |
Improved gamma amino butyric acid analogs
|
EP1137414B1
(fr)
|
1998-12-11 |
2005-10-12 |
Bonnie M. Davis |
Utilisation d'inhibiteurs d'acetylcholine esterase pour la modulation de l'axe hypothalamo-hypophyso-gonadique
|
UA62015C2
(en)
|
1998-12-28 |
2003-12-15 |
Pfizer Prod Inc |
Benzoizoxazol derivatives, a pharmaceutical composition (variants) based thereon (variants) and a method for treatment (variants)
|
US6271380B1
(en)
|
1998-12-30 |
2001-08-07 |
Dupont Pharmaceuticals Company |
1H-imidazo[4,5-d]pyridazin-7-ones, 3H-imidazo-[4,5-c]pyridin-4-ones and corresponding thiones as corticotropin releasing factor (CRF) receptor ligands
|
WO2000041684A1
(fr)
|
1999-01-13 |
2000-07-20 |
Warner-Lambert Company |
Produit compose pharmaceutique pour le traitement des depressions
|
DK1033364T3
(da)
|
1999-03-01 |
2005-06-06 |
Pfizer Prod Inc |
Cyanholdige oxamidsyrer og -derivater som thyroideareceptorligander
|
WO2000051971A1
(fr)
|
1999-03-01 |
2000-09-08 |
Pfizer Products Inc. |
Acides oxamiques et derives utilises en tant que ligands du recepteur des hormones thyroidiennes
|
US6277866B1
(en)
|
1999-03-03 |
2001-08-21 |
Eisai Co., Ltd. |
1-benzyl-4[(5,6-dimethoxy-2-fluoro-1-indanon)-2-yl]methylpiperidine
|
DE69913138T2
(de)
|
1999-03-31 |
2004-08-26 |
Eisai Co., Ltd. |
Stabilisierte zusammensetzung mit nootropen wirkstoffen
|
EP1050303A3
(fr)
|
1999-04-27 |
2003-01-15 |
Pfizer Products Inc. |
Methodes et compositions pour le traitement des troubles du comportement liées à l'age des animaux de compagnie
|
EE200100611A
(et)
|
1999-05-21 |
2003-02-17 |
Pfizer Products Inc. |
NOS inhibiitorite uued farmatseutilised kombinatsioonid
|
WO2000074784A1
(fr)
|
1999-06-09 |
2000-12-14 |
Eli Lilly And Company |
Combinaison pour le traitement du gain de poids lie a la prise de medicaments antipsychotiques comprenant un antipsychotique atypique et un antagoniste de type h2
|
US6713471B1
(en)
|
1999-06-15 |
2004-03-30 |
Bristol-Myers Squibb Pharma Company |
Substituted heterocycle fused gamma-carbolines
|
BR0012086A
(pt)
|
1999-06-15 |
2002-04-02 |
Bristol Myers Squibb Pharma Co |
Compostos derivados de gama-carbolinas fundidas com heterociclos substituìdos, composição farmacêutica e usos dos compostos
|
AU6053900A
(en)
|
1999-06-25 |
2001-01-31 |
Morris Notelovitz |
Compositions for treating or preventing neurodegeneration and cognitive decline
|
US6432989B1
(en)
|
1999-08-27 |
2002-08-13 |
Pfizer Inc |
Use of CRF antagonists to treat circadian rhythm disorders
|
DK1209151T3
(da)
|
1999-09-01 |
2007-08-20 |
Eisai R&D Man Co Ltd |
4-substituerede piperidinderivativer
|
JP4242048B2
(ja)
|
1999-09-01 |
2009-03-18 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
4−置換ピペリジン誘導体
|
AU5786300A
(en)
|
1999-09-22 |
2001-04-24 |
Schering Corporation |
Muscarinic antagonists
|
DE60020786T2
(de)
|
1999-09-30 |
2006-03-23 |
Pfizer Products Inc., Groton |
6-Azauracilderivate als Liganden der Thyroidrezeptoren
|
CA2324813A1
(fr)
|
1999-11-10 |
2001-05-10 |
Susan Beth Sobolov-Jaynes |
Traitement combine de la depression et de l'anxiete
|
US6620802B1
(en)
|
1999-11-23 |
2003-09-16 |
Corcept Therapeutics, Inc. |
Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist
|
DE60034815T2
(de)
|
1999-12-01 |
2008-01-31 |
Ucb S.A. |
Ein pyrrolidinacetatderivat zur behandlung von chronischem oder neuropathischem schmerz
|
JP2003516992A
(ja)
|
1999-12-17 |
2003-05-20 |
デュポン ファーマシューティカルズ カンパニー |
イミダゾピリミジニル誘導体およびイミダゾピリジニル誘導体
|
JP2003517481A
(ja)
|
1999-12-17 |
2003-05-27 |
ブリストルーマイヤーズ スクイブ カンパニー |
抗精神病複素環式化合物
|
EP1246822A1
(fr)
|
1999-12-20 |
2002-10-09 |
Eli Lilly And Company |
Derives de benzofuranne
|
WO2001046186A1
(fr)
|
1999-12-20 |
2001-06-28 |
Eli Lilly And Company |
Derives de benzofuranne
|
EP1242419A1
(fr)
|
1999-12-20 |
2002-09-25 |
Eli Lilly And Company |
Derives d'azabicyclo 3.2.1]octane
|
EP1242411B1
(fr)
|
1999-12-20 |
2006-03-08 |
Eli Lilly And Company |
Derives de l'indole destines au traitement de depression et d'anxiete
|
WO2001046179A1
(fr)
|
1999-12-20 |
2001-06-28 |
Eli Lilly And Company |
Derives de piperidine et leur utilisation comme antagonistes du recepteur de la serotonine
|
EP1113015B1
(fr)
|
1999-12-29 |
2004-09-15 |
Pfizer Products Inc. |
Dérivés de 3-((2-pipérazinyl-phényle)méthyle)-1-(4-(trifluorométhyl)-phényl)-2-pyrrolidinone optiquement actifs utilisés en tant qu'antagonistes sélectifs du recepteurs de 5-HT 1D
|
EP1127882A1
(fr)
|
2000-01-25 |
2001-08-29 |
Pfizer Products Inc. |
Composés tétrazoliques comme ligands du récepteur thyroid
|
CZ20022771A3
(cs)
|
2000-02-17 |
2003-09-17 |
Bristol-Myers Squibb Company |
Ligandy thyreoidního receptoru odvozené od anilinu
|
GB0004297D0
(en)
|
2000-02-23 |
2000-04-12 |
Ucb Sa |
2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
|
WO2001066114A1
(fr)
*
|
2000-03-03 |
2001-09-13 |
Eisai Co., Ltd. |
Nouvelles methodes reposant sur l'utilisation d'inhibiteurs de cholinesterase
|
AU2001239052A1
(en)
|
2000-03-06 |
2001-09-17 |
Immune Network Ltd. |
Compositions for prevention and treatment of dementia
|
AU2001241512A1
(en)
|
2000-03-13 |
2001-09-24 |
Eli Lilly And Company |
Sulfonamide derivatives
|
US6664291B2
(en)
|
2000-03-31 |
2003-12-16 |
Pfizer, Inc. |
Malonamic acids and derivatives thereof as thyroid receptor ligands
|
WO2001072692A1
(fr)
|
2000-03-31 |
2001-10-04 |
Pfizer Products Inc. |
Acides malonamiques et leurs derives en tant que ligands du recepteur de thyroide
|
GB0007884D0
(en)
|
2000-03-31 |
2000-05-17 |
Pfizer Ltd |
Diphenyl ether compounds useful in therapy
|
EP1280798B1
(fr)
|
2000-04-08 |
2007-01-03 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Heterocycles bicycliques, medicaments contenant ces composes, leur utilisation et leur procede de production
|
OA12245A
(en)
|
2000-04-10 |
2003-11-10 |
Pfizer Prod Inc |
Benzoamide piperidine compounds as substance P antagonists.
|
WO2001078728A1
(fr)
|
2000-04-13 |
2001-10-25 |
Eisai Co., Ltd. |
Inhibiteurs d'acetylcholinesterases contenant des sels de 1-benzyl-pyridinium
|
US6620830B2
(en)
|
2000-04-21 |
2003-09-16 |
Pfizer, Inc. |
Thyroid receptor ligands
|
US20010036949A1
(en)
|
2000-05-09 |
2001-11-01 |
Coe Jotham Wadsworth |
Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal
|
US6630469B2
(en)
|
2000-05-09 |
2003-10-07 |
Bristol-Myers Squibb Company |
5-HT7 receptor antagonists
|
US20040229911A1
(en)
|
2000-05-17 |
2004-11-18 |
Pfizer Inc |
New pharmaceutical combinations for NOS inhibitors
|
EP1292311A2
(fr)
|
2000-05-24 |
2003-03-19 |
Eli Lilly And Company |
Combinaison d'un antidepresseur et d'un potentialisateur des recepteurs ampa pour traiter la depression
|
AU2001263486A1
(en)
|
2000-05-26 |
2001-12-11 |
Bristol-Myers Squibb Company |
Human KCNQ5 potassium channel, methods and compositions thereof
|
DE60124093D1
(de)
|
2000-06-02 |
2006-12-07 |
Pfizer Prod Inc |
S-methyl-dihydro-ziprasidon zur Behandlung von Augenerkrankungen.
|
US6395784B1
(en)
|
2000-06-07 |
2002-05-28 |
Bristol-Myers Squibb Company |
Benzamide ligands for the thyroid receptor
|
AU2001268055A1
(en)
|
2000-06-30 |
2002-01-14 |
Eli Lilly And Company |
Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist
|
DOP2001000189A
(es)
|
2000-06-30 |
2002-03-30 |
Pfizer Prod Inc |
Benzofenonas y sulfonas como inhibidores de la captación de glicina
|
US6630476B2
(en)
|
2000-07-07 |
2003-10-07 |
Bristol-Myers Squibb Pharma Company |
Pyrrolo [3,4-d] pyrimidines as corticotropin releasing factor (CRF) antagonists
|
EP1177792A3
(fr)
|
2000-07-27 |
2002-10-23 |
Pfizer Products Inc. |
Ligands dopamine d4 destines au traitement des troubles associees a la cherche de la nouveaute
|
US20020016334A1
(en)
|
2000-07-31 |
2002-02-07 |
Coe Jotham Wadsworth |
Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
|
US6756385B2
(en)
|
2000-07-31 |
2004-06-29 |
Pfizer Inc. |
Imidazole derivatives
|
US20020049211A1
(en)
|
2000-09-06 |
2002-04-25 |
Sobolov-Jaynes Susan Beth |
Combination treatment for depression and anxiety
|
AU2001282913A1
(en)
|
2000-09-08 |
2002-03-22 |
Eli Lilly And Company |
A method of treating weight gain associated with atypical antipsychotic use
|
US6515005B2
(en)
|
2000-09-21 |
2003-02-04 |
Bristol-Myers Squibb Company |
Substituted azole derivatives as inhibitors of corticotropin releasing factor
|
EP1192952A3
(fr)
|
2000-09-28 |
2003-03-26 |
Pfizer Products Inc. |
Composition pour le traitement de la dépression et de l'anxieté contenant un antagoniste du recepteur NK-3 et un antagoniste du récepteur NK-1
|
IL145584A0
(en)
|
2000-10-02 |
2002-06-30 |
Pfizer Prod Inc |
Nmda nr2b antagonists for treatment
|
US20020151591A1
(en)
|
2000-10-17 |
2002-10-17 |
Anabella Villalobos |
Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders
|
US20020103198A1
(en)
|
2000-12-04 |
2002-08-01 |
Fliri Anton F.J |
Acylamino cyclopropane derivatives
|
CA2364211A1
(fr)
|
2000-12-05 |
2002-06-05 |
Phillip Branch Chappell |
Traitement combine de la depression, de l'anxiete et de la psychose
|
UA73619C2
(en)
|
2000-12-13 |
2005-08-15 |
Pfizer Prod Inc |
Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
|
US6849619B2
(en)
|
2000-12-20 |
2005-02-01 |
Bristol-Myers Squibb Company |
Substituted pyridoindoles as serotonin agonists and antagonists
|
RU2003121406A
(ru)
|
2000-12-20 |
2004-12-27 |
Бристол-Маерс Сквибб Фарма Компани (Us) |
Производные замещенных пиразинохиноксалинов в качестве агонистов и антагонистов рецептора серотонина
|
PL366627A1
(en)
|
2000-12-20 |
2005-02-07 |
Bristol-Myers Squibb Company |
Substituted pyrroloquinolines and pyridoquinolines as serotonin agonists and antagonists
|
PL366233A1
(en)
|
2000-12-20 |
2005-01-24 |
Bristol-Myers Squibb Company |
Substituted pyridoindoles as serotonin agonists and antagonists
|
WO2002053153A1
(fr)
|
2000-12-28 |
2002-07-11 |
Daiichi Pharmaceutical Co., Ltd. |
Medicaments permettant de traiter et de prevenir une douleur neurologique
|
US20020086871A1
(en)
|
2000-12-29 |
2002-07-04 |
O'neill Brian Thomas |
Pharmaceutical composition for the treatment of CNS and other disorders
|
US6436938B1
(en)
|
2001-01-22 |
2002-08-20 |
Pfizer Inc. |
Combination treatment for depression
|
RU2003126188A
(ru)
|
2001-01-26 |
2005-03-27 |
Бристол-Маерс Сквибб Компани (Us) |
Имидазолильные производные как ингибиторы кортикотропин-рилизинг фактора
|
US20020107244A1
(en)
|
2001-02-02 |
2002-08-08 |
Howard Harry R. |
Combination treatment for depression
|
US6610326B2
(en)
|
2001-02-16 |
2003-08-26 |
Andrx Corporation |
Divalproex sodium tablets
|
CA2438930A1
(fr)
|
2001-02-23 |
2002-09-06 |
Johns Hopkins University |
Traitement des tics, tremblements et troubles afferents
|
US20020123490A1
(en)
|
2001-03-01 |
2002-09-05 |
Pfizer Inc. |
Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis
|
WO2002072101A1
(fr)
|
2001-03-13 |
2002-09-19 |
Bristol-Myers Squibb Pharma Company |
Ligand du recepteur de la corticoliberine, son enantiomere et ses sels pharmaceutiquement acceptables
|
RU2292347C2
(ru)
|
2001-03-13 |
2007-01-27 |
Бристоль-Мейерз Сквибб Фарма Компани |
4-(2-БУТИЛАМИНО)-2,7-ДИМЕТИЛ-8-(2-МЕТИЛ-6-МЕТОКСИПИРИД-3-ИЛ)ПИРАЗОЛО-[1,5-а]-1,3,5-ТРИАЗИН, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ЕГО СОДЕРЖАЩАЯ, И ЕГО ПРИМЕНЕНИЕ
|
US20020187977A1
(en)
|
2001-03-15 |
2002-12-12 |
Rodney Pearlman |
Methods for restoring cognitive function following systemic stress
|
DK1379239T3
(da)
|
2001-03-29 |
2008-01-07 |
Lilly Co Eli |
N(2-aryl-ethyl)-benzyl-aminer som antagonister af 5 HT6 receptoren
|
SK12012003A3
(en)
|
2001-03-29 |
2004-10-05 |
Bristol Myers Squibb Co |
Cyclopropylindole derivatives as selective serotonin reuptake inhibitors
|
PL366406A1
(en)
|
2001-04-19 |
2005-01-24 |
Warner-Lambert Company Llc |
Fused bicyclic or tricyclic amino acids
|
US20030018047A1
(en)
|
2001-04-20 |
2003-01-23 |
Pfizer Inc. |
Therapeutic use of selective PDE10 inhibitors
|
EP1666886A3
(fr)
|
2001-04-20 |
2006-06-21 |
Pfizer Products Inc. |
Méthode d'identification d'un inhibiteur sélectif de la PDE10
|
US20030032579A1
(en)
|
2001-04-20 |
2003-02-13 |
Pfizer Inc. |
Therapeutic use of selective PDE10 inhibitors
|
IL149106A0
(en)
|
2001-04-20 |
2002-11-10 |
Pfizer Prod Inc |
Therapeutic use of selective pde10 inhibitors
|
AU2756602A
(en)
|
2001-04-25 |
2002-10-31 |
Pfizer Products Inc. |
Methods and kits for treating depression or preventing deterioration of cognitive function
|
MY129350A
(en)
|
2001-04-25 |
2007-03-30 |
Bristol Myers Squibb Co |
Aripiprazole oral solution
|
US20020165217A1
(en)
|
2001-05-01 |
2002-11-07 |
Pfizer Inc. |
Combination treatment for anxiety and depression
|
EP1256578B1
(fr)
|
2001-05-11 |
2006-01-11 |
Pfizer Products Inc. |
Dérivés de thiazole et leur utilisation comme inhibiteurs de cdk
|
SK13752003A3
(en)
|
2001-05-14 |
2004-11-03 |
Bristol Myers Squibb Pharma Co |
Substituted pyrazinones, pyridines and pyrimidines as ligands of factor releasing corticotropine
|
WO2002094787A1
(fr)
|
2001-05-23 |
2002-11-28 |
Ucb, S.A. |
Derives d'acide alcanoique 2-oxo-piperidinyl- et 2-oxo-azepanyle destines au traitement de l'epilepsie et d'autres troubles neurologiques
|
EP1260221A3
(fr)
|
2001-05-23 |
2002-12-18 |
Pfizer Products Inc. |
Therapie de combinaison de la depression et de l'anxieté
|
US6566550B2
(en)
|
2001-06-21 |
2003-05-20 |
Pfizer Inc |
Substituted aromatic ethers as inhibitors of glycine transport
|
US20030008892A1
(en)
|
2001-07-09 |
2003-01-09 |
Pfizer Inc. |
Pharmaceutical composition and method of modulating cholinergic function in a mammal
|
US6894045B2
(en)
|
2001-07-12 |
2005-05-17 |
Bristol-Myers Squibb Pharma Company |
Tetrahydropurinones and derivatives thereof as corticotropin releasing factor receptor ligands
|
US7276526B2
(en)
|
2001-07-13 |
2007-10-02 |
Bristol-Myers Squibb Pharma Company |
Substituted thiazoles and oxazoles as corticotropin releasing hormone ligands
|
EP1417203A4
(fr)
|
2001-07-24 |
2005-08-10 |
Bristol Myers Squibb Co |
S-6-hydroxy-buspirone
|
US6686361B2
(en)
|
2001-07-24 |
2004-02-03 |
Bristol-Myers Squibb Company |
R-6-hydroxy-buspirone
|
US8354438B2
(en)
|
2001-08-08 |
2013-01-15 |
Michael Chez |
Neurological functions
|
ATE305917T1
(de)
|
2001-08-16 |
2005-10-15 |
Pfizer Prod Inc |
Difluormethylen aromatische ether und ihre verwendung als inhibitoren des glycin-typ-1- transporters
|
CA2457982C
(fr)
|
2001-08-22 |
2009-11-03 |
Daiichi Pharmaceutical Co., Ltd. |
Utilisation de la nefiracetame dans le traitement de la neurodegenerescence
|
WO2003020289A1
(fr)
|
2001-08-30 |
2003-03-13 |
Ortho-Mcneil Pharmaceutical, Inc. |
Traitement de la demence et des troubles de la memoire par le biais d'anticonvulsifs et d'inhibiteurs de l'acetylcholinesterase
|
US7297708B2
(en)
|
2001-09-06 |
2007-11-20 |
Bristol-Myers Squibb Company |
Heteroaromatic substituted cyclopropane as corticotropin releasing hormone ligands
|
DE60208132T2
(de)
|
2001-09-26 |
2006-07-20 |
Pfizer Products Inc., Groton |
Indolcaroboxylsäure als Thyroidrezeptor-Liganden
|
US20040235957A1
(en)
|
2001-10-12 |
2004-11-25 |
David Bleakman |
Use of sulfonamide derivatives as pharmaceuticals compounds
|
JP4484515B2
(ja)
|
2001-10-16 |
2010-06-16 |
メモリ ファーマセチカル コーポレーション |
神経病症候群の治療の為のpde−4阻害剤としての、4−(4−アルコキシ−3−ヒドロキシフェニル)−2−ピロリディン誘導体。
|
KR20010113584A
(ko)
|
2001-11-08 |
2001-12-28 |
(주)시스튜디오 |
컴퓨터에 의한 만화 애니메이션 구현방법 및 만화애니메이션 실행데이터를 기록한 컴퓨터로 읽을 수 있는기록매체
|
US6673811B1
(en)
|
2001-11-19 |
2004-01-06 |
Neurogen Corporation |
1H-pyrrolo [3,2-b] pyridine-3-carboxylic acid amines as GABAA receptor ligands
|
WO2003043637A1
(fr)
|
2001-11-20 |
2003-05-30 |
Bristol-Myers Squibb Pharma Company |
Derives de 3,7-dihydro-purine-2,6-dione utilises comme ligands du recepteur de crf
|
US6992087B2
(en)
|
2001-11-21 |
2006-01-31 |
Pfizer Inc |
Substituted aryl 1,4-pyrazine derivatives
|
MXPA02010430A
(es)
|
2001-11-27 |
2003-06-02 |
Warner Lambert Co |
Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.
|
BR0213581A
(pt)
|
2001-12-11 |
2004-08-24 |
Lilly Co Eli |
Uso de um inibidor de recaptação de norepinefrina seletivo
|
US6495700B1
(en)
|
2002-01-09 |
2002-12-17 |
Axonyx, Inc. |
Process for producing phenserine and its analog
|
US20050014848A1
(en)
|
2002-01-23 |
2005-01-20 |
Pfizer Inc. |
Combination of serotonin reuptake inhibitors and norephinephrine reuptake inhibitors
|
US20050009927A1
(en)
|
2002-01-23 |
2005-01-13 |
Pfizer Inc |
Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors
|
EP1476165A1
(fr)
|
2002-02-22 |
2004-11-17 |
PHARMACIA & UPJOHN COMPANY |
Pyrimidinones et pyrimidinthiones substitues
|
US20040167200A1
(en)
|
2002-03-25 |
2004-08-26 |
Pfizer Inc. |
Pharmaceutical composition and method of modulating cholinergic function in a mammal
|
GB0207104D0
(en)
|
2002-03-26 |
2002-05-08 |
Pfizer Ltd |
Stable hydrate of a muscarinic receptor antagonist
|
US6759552B2
(en)
|
2002-03-28 |
2004-07-06 |
Council Of Scientific And Industrial Research |
Compound as cholinesterase inhibitor and its isolation from fungus sporotrichum species
|
EP1492794B1
(fr)
|
2002-03-28 |
2007-12-12 |
Eli Lilly And Company |
Aryles benzodiazepines a substitution de piperazine et leur utilisation en tant qu'antagonistes de recepteur de dopamine dans le traitement de troubles psychotiques
|
AU2003221117A1
(en)
|
2002-03-29 |
2003-10-13 |
Eisai Co., Ltd. |
(1-indanone)-(1,2,3,6-tetrahydropyridine) derivative
|
WO2003084610A1
(fr)
|
2002-04-03 |
2003-10-16 |
Eli Lilly And Company |
Traitement des psychoses associant un antipsychotique atypique et un antagoniste du recepteur mglu2/3
|
CA2484217A1
(fr)
|
2002-04-26 |
2003-11-06 |
Schering Corporation |
Antagonistes muscariniques
|
US6713490B2
(en)
|
2002-04-26 |
2004-03-30 |
Pfizer, Inc. |
3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists
|
WO2004034963A2
(fr)
|
2002-05-17 |
2004-04-29 |
Eisai Co., Ltd. |
Methodes et compositions utilisant des inhibiteurs de la cholinesterase
|
AU2003227516B2
(en)
|
2002-05-31 |
2008-03-20 |
H. Lundbeck A/S |
A combination of an NMDA-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
|
US6710040B1
(en)
|
2002-06-04 |
2004-03-23 |
Pfizer Inc. |
Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
|
US20040001895A1
(en)
|
2002-06-17 |
2004-01-01 |
Pfizer Inc. |
Combination treatment for depression and anxiety
|
US20030235631A1
(en)
|
2002-06-17 |
2003-12-25 |
Pfizer Inc. |
Combination treatment for depression and anxiety
|
US20040006135A1
(en)
|
2002-06-19 |
2004-01-08 |
Pfizer Inc. |
Combination treatment for depression and anxiety
|
US20040116506A1
(en)
|
2002-06-20 |
2004-06-17 |
Krusz John Claude |
Use of levetiracetam for treating or preventing acute headaches
|
US6875771B2
(en)
|
2002-07-26 |
2005-04-05 |
Bristol-Myers Squibb Company |
Pyridopyrimidine derivatives as 5-HT6 antagonists
|
US7384934B2
(en)
|
2002-08-05 |
2008-06-10 |
Eli Lilly And Company |
Piperazine substituted aryl benzodiazepines
|
US7557137B2
(en)
|
2002-08-05 |
2009-07-07 |
Bristol-Myers Squibb Company |
Gamma-lactams as beta-secretase inhibitors
|
US7053122B2
(en)
|
2002-08-09 |
2006-05-30 |
Pfizer Inc |
Therapeutic use of aryl amino acid derivatives
|
GB0219153D0
(en)
|
2002-08-16 |
2002-09-25 |
Pfizer Ltd |
Substituted glycine derivatives for use as medicaments
|
GB0219154D0
(en)
|
2002-08-16 |
2002-09-25 |
Pfizer Ltd |
Diaryl compounds
|
ES2322953T3
(es)
|
2002-08-20 |
2009-07-02 |
Bristol-Myers Squibb Company |
Formulacion del complejo de aripiprazol y procedimiento.
|
CA2498291C
(fr)
|
2002-09-10 |
2009-04-07 |
Pfizer Products Inc. |
Composes diazabicycliques utilises dans le traitement de troubles associes au snc
|
US7049314B2
(en)
|
2002-09-18 |
2006-05-23 |
Bristol-Myers Squibb Company |
Cyclopentyl indole derivatives
|
TW200418838A
(en)
|
2002-09-18 |
2004-10-01 |
Bristol Myers Squibb Co |
Compounds for the treatment of premature ejaculation
|
US7635709B2
(en)
|
2002-09-26 |
2009-12-22 |
The United States Of America As Represented By The Department Of Veterans Affairs |
Compositions and methods for bowel care in individuals with chronic intestinal pseudo-obstruction
|
US7067658B2
(en)
|
2002-09-30 |
2006-06-27 |
Bristol-Myers Squibb Company |
Pyridino and pyrimidino pyrazinones
|
GB0223494D0
(en)
|
2002-10-09 |
2002-11-13 |
Neuropharma Sa |
Dual binding site acetylcholinesterase inhibitors for the treatment of alzheimer's disease
|
RU2005112254A
(ru)
|
2002-10-24 |
2006-01-20 |
Пфайзер Продактс Инк. (Us) |
Ацильные производные 5-(1,2-бензизотиазол-3-ил)-1-пиперазинил)этил)-6-хлор-1,3-дигидро-2н-индол-2-она, обладающие нейролептической активностью
|
TW200418446A
(en)
|
2002-10-24 |
2004-10-01 |
Merz Pharma Gmbh & Co Kgaa |
Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
|
GB0225379D0
(en)
|
2002-10-31 |
2002-12-11 |
Pfizer Ltd |
Therapeutic proline derivatives
|
CA2502068A1
(fr)
|
2002-11-18 |
2004-06-03 |
Pfizer Products Inc. |
Amides cycliques fluores inhibant la dipeptidyl peptidase iv
|
EP1581516A4
(fr)
|
2002-11-22 |
2007-10-17 |
Bristol Myers Squibb Co |
Derives de 3-heterocyclique benzylamide utilises en tant qu'agents d'ouverture de canal potassique
|
WO2004047739A2
(fr)
|
2002-11-22 |
2004-06-10 |
Bristol-Myers Squibb Company |
Amides de pyridinyle, pyrimidinyle et pyrazinyle utilises en tant qu'agents d'ouverture des canaux potassiques
|
AU2003294443A1
(en)
|
2002-11-22 |
2004-06-18 |
Bristol-Myers Squibb Company |
3-(pyridinyl-piperazin-1-yl)-phenylethyl amides as potassium channel openers
|
AU2003294441A1
(en)
|
2002-11-22 |
2004-06-18 |
Bristol-Myers Squibb Company |
1-aryl-2-hydroxyethyl amides as potassium channel openers
|
EP1565190A4
(fr)
|
2002-11-22 |
2006-04-26 |
Bristol Myers Squibb Co |
Amides arylcyclopropylcarboxyliques utilises en tant qu'agents d'ouverture des canaux potassiques
|
CN101249091A
(zh)
|
2002-11-22 |
2008-08-27 |
约翰斯·霍普金斯大学 |
治疗认知功能障碍的靶位
|
US20070135514A1
(en)
|
2002-12-03 |
2007-06-14 |
Berkley Lynch |
Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
|
US7090985B2
(en)
|
2002-12-03 |
2006-08-15 |
Ucb, S.A. |
Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
|
WO2004052461A1
(fr)
|
2002-12-11 |
2004-06-24 |
Pharmacia & Upjohn Company Llc |
Traitement combine de troubles deficitaires de l'attention avec hyperactivite
|
BR0317110A
(pt)
|
2002-12-11 |
2005-10-25 |
Pharmacia & Upjohn Co Llc |
Tratamento de doenças com combinações de agonistas do receptor nicotìnico da acetilcolina alfa 7 e outros compostos
|
BRPI0406704A
(pt)
|
2003-01-31 |
2005-12-20 |
Pfizer Prod Inc |
Antagonistas de 5ht~7~ e agonistas inversos
|
CA2517845A1
(fr)
|
2003-03-06 |
2004-09-23 |
Celgene Corporation |
Methodes d'utilisation et compositions comprenant des medicaments selectifs inhibitoires de cytokine pour le traitement et pour la gestion de troubles du systeme nerveux central
|
RS20050692A
(en)
|
2003-03-12 |
2007-11-15 |
Pfizer Production Inc., |
Pyridyloxymethyl and benzisoxazole azabicyclic derivatives
|
US20040191334A1
(en)
|
2003-03-24 |
2004-09-30 |
Pang-Chui Shaw |
Use of transhinone derivates as cholinesterase inhibitors in treating related diseases
|
ITMI20030573A1
(it)
|
2003-03-24 |
2004-09-25 |
Nikem Research Srl |
Composti ad azione nootropica, loro preparazione,
|
JP2006521343A
(ja)
|
2003-03-27 |
2006-09-21 |
ファイザー・プロダクツ・インク |
置換4−アミノ[1,2,4]トリアゾロ[4,3−a]キノキサリン
|
TW200508197A
(en)
|
2003-03-31 |
2005-03-01 |
Ucb Sa |
Indolone-acetamide derivatives, processes for preparing them and their uses
|
US7041671B2
(en)
|
2003-04-02 |
2006-05-09 |
Pfizer Inc |
Pyrrolo[1,2-b]pyridazine compounds and their uses
|
US7056920B2
(en)
|
2003-04-04 |
2006-06-06 |
Pfizer Inc |
Pyrrolo[1,2-B]pyridazine compounds and their uses
|
US7034023B2
(en)
|
2003-04-04 |
2006-04-25 |
Pfizer Inc |
Pyrrolo[1,2-B]pyridazine compounds and their uses
|
US20040204453A1
(en)
|
2003-04-14 |
2004-10-14 |
Pfizer Inc |
4-Phenyl-piperidine compounds and their use as modulators of opioid receptors
|
US7056930B2
(en)
|
2003-04-14 |
2006-06-06 |
Pfizer Inc. |
2-Azabicyclo[3.3.1]nonane derivatives
|
MXPA05011070A
(es)
|
2003-04-14 |
2005-12-12 |
Pfizer Prod Inc |
Derivados de 3-azabiciclo [3.2.1] octano.
|
US7112585B2
(en)
|
2003-04-18 |
2006-09-26 |
Bristol-Myers Squibb Company |
Pyrimidine derivatives as corticotropin releasing factor inhibitors
|
US7030145B2
(en)
|
2003-04-18 |
2006-04-18 |
Bristol-Myers Squibb Company |
Pyridinyl derivatives for the treatment of depression
|
CA2522803A1
(fr)
|
2003-04-23 |
2004-11-04 |
Pharmacia & Upjohn Company Llc |
Pyrimidinones et pyrimidinthiones substituees en tant qu'antagonistes de la corticoliberine
|
GB0309440D0
(en)
|
2003-04-25 |
2003-06-04 |
Lilly Co Eli |
Quinolone derivatives
|
US7732162B2
(en)
|
2003-05-05 |
2010-06-08 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
|
BRPI0410097A
(pt)
|
2003-05-07 |
2006-05-16 |
Pharmacia & Upjohn Co Llc |
compostos de pirrol[1,2-b]piridazina
|
WO2004099148A1
(fr)
|
2003-05-09 |
2004-11-18 |
Pharmacia & Upjohn Company Llc |
Derives pyrimidiques substitues
|
WO2004100956A1
(fr)
|
2003-05-16 |
2004-11-25 |
Pfizer Products Inc. |
Procede pour ameliorer les fonctions cognitives en administrant du ziprasidone
|
WO2004100992A2
(fr)
|
2003-05-16 |
2004-11-25 |
Pfizer Products Inc. |
Combinaisons therapeutiques d'antipsychotiques atypiques avec des modulateurs de l'acide 4-aminobutanoique et/ou des medicaments anticonvulsivants
|
JP2007516955A
(ja)
|
2003-05-16 |
2007-06-28 |
ファイザー・プロダクツ・インク |
双極性障害および関連症候の治療
|
EP1633360A1
(fr)
|
2003-05-16 |
2006-03-15 |
Pfizer Products Incorporated |
Traitement de troubles psychotiques et depressifs
|
EP2601953A1
(fr)
|
2003-05-23 |
2013-06-12 |
Otsuka Pharmaceutical Co., Ltd. |
Dérives de carbostyrile et psychorégulateurs pour traiter les troubles de l'humeur
|
US7101881B2
(en)
|
2003-06-11 |
2006-09-05 |
Pfizer Inc |
Tetrahydroquinolines
|
MXPA05013756A
(es)
|
2003-06-18 |
2006-03-08 |
Pfizer Prod Inc |
Piperazinil-ariloxi y piperazinil-heteroariloxi-n-aril-lactamas novedosas.
|
EP1641454B1
(fr)
|
2003-06-27 |
2008-10-01 |
Pfizer Products Inc. |
Pyrazolo[3,4-b]pyridin-6-ones a titre d'inhibiteurs de gsk-3
|
WO2005000304A1
(fr)
|
2003-06-27 |
2005-01-06 |
Pfizer Products Inc. |
Pyrazolo[3,4-b]pyridin-6-ones en tant qu'inhibiteurs de la gsk-3
|
US20050070577A1
(en)
|
2003-07-03 |
2005-03-31 |
Pfizer Inc. |
Compositions containing a serotonin selective reuptake inhibitor and a 5-HT2A receptor antagonist
|
WO2005013961A1
(fr)
|
2003-07-17 |
2005-02-17 |
Eli Lilly And Company |
Polytherapie pour le traitement de troubles cognitifs ou de psychoses
|
TW200510324A
(en)
|
2003-08-11 |
2005-03-16 |
Lilly Co Eli |
6-(2,2,2-trifluoroethylamino)-7-chiloro-2, 3, 4, 5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist
|
WO2005019168A2
(fr)
|
2003-08-20 |
2005-03-03 |
Pfizer Products Inc. |
Derives fluores de lysine en tant qu'inhibiteurs de la dipeptidylpeptidase iv
|
MXPA06002778A
(es)
|
2003-09-09 |
2006-06-14 |
Pfizer Prod Inc |
Combinacion de inhibidores de recaptacion de serotonina e inhibidores de recaptacion de norepinefrina.
|
WO2005026177A1
(fr)
|
2003-09-09 |
2005-03-24 |
Eli Lilly And Company |
Piperazines substitutees d'azepines, d'oxazepines, et de thiazepines
|
GB0322140D0
(en)
|
2003-09-22 |
2003-10-22 |
Pfizer Ltd |
Combinations
|
US7244843B2
(en)
|
2003-10-07 |
2007-07-17 |
Bristol-Myers Squibb Company |
Modulators of serotonin receptors
|
MXPA06003748A
(es)
|
2003-10-08 |
2006-06-14 |
Pfizer |
Compuestos de lactama condensada.
|
DE602004021011D1
(de)
|
2003-10-08 |
2009-06-18 |
Lilly Co Eli |
Pyrrol- und pyrazolderivate als potentiatoren von glutamatrezeptoren
|
US20050080100A1
(en)
|
2003-10-09 |
2005-04-14 |
Pfizer Inc |
Pyridylamino compounds and methods of use thereof
|
EP2269608A3
(fr)
|
2003-10-16 |
2011-02-16 |
NeuroSearch AS |
Compositions pharmaceutiques comprenants des inhibiteurs de récaptage de neurotransmitteurs monoamine et des inhibiteurs de l'acétylcholinestérase
|
CA2540860A1
(fr)
|
2003-10-16 |
2005-04-28 |
Pfizer Products Inc. |
Preparation de derives de 3-azabicyclo [3.1.0] hexane
|
CA2543322A1
(fr)
|
2003-10-21 |
2005-05-12 |
Sention, Inc. |
Esters de carbamoyle inhibant la cholinesterase et liberant des agents pharmacologiquement actifs
|
WO2005051488A1
(fr)
|
2003-11-26 |
2005-06-09 |
Pfizer Products Inc. |
Association d'agonistes de la dopamine et d'inhibiteurs de recaptage de la monoamine
|
WO2005053701A1
(fr)
|
2003-11-26 |
2005-06-16 |
Pfizer Products Inc. |
Association d'agonistes de la dopamine et d'imides et lactames heterocycliques d'aralkyle et d'aralkylidene
|
WO2005051919A1
(fr)
|
2003-11-26 |
2005-06-09 |
Pfizer Products Inc. |
Derives d'aminopyrazole en tant qu'inhibiteurs de la gsk-3
|
EP2050736A1
(fr)
|
2003-12-02 |
2009-04-22 |
UCB Pharma, S.A. |
Dérivés d'imidazol, leurs procédés de préparation et leurs utilisations
|
CA2548304A1
(fr)
|
2003-12-12 |
2005-07-07 |
Eli Lilly And Company |
Traitement des bouffees de chaleur, des troubles du controle des impulsions et du changement de personnalite consecutifs a un etat pathologique general
|
US20050227980A1
(en)
|
2003-12-15 |
2005-10-13 |
Pfizer Inc. |
Aralkyl and aralkylidene heterocyclic lactam and imides
|
JP2007513995A
(ja)
|
2003-12-15 |
2007-05-31 |
ファイザー・プロダクツ・インク |
アラルキルおよびアラルキリデン複素環式ラクタムおよびイミド
|
OA13344A
(en)
|
2003-12-19 |
2007-04-13 |
Pfizer |
Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-HSD-1) for the treatment of diabetes and obesity.
|
BRPI0418092A
(pt)
|
2003-12-23 |
2007-04-17 |
Pfizer Prod Inc |
combinação terapêutica para melhora cognitiva e transtornos psicóticos
|
TW200522944A
(en)
|
2003-12-23 |
2005-07-16 |
Lilly Co Eli |
CB1 modulator compounds
|
US20050171095A1
(en)
|
2004-01-06 |
2005-08-04 |
Pfizer Inc |
Combination of CRF antagonists and 5-HT1B receptor antagonists
|
ATE552251T1
(de)
|
2004-01-09 |
2012-04-15 |
Lilly Co Eli |
Thiophen- und furanverbindungen
|
WO2005072713A2
(fr)
|
2004-01-27 |
2005-08-11 |
The Feinstein Institute For Medical Research |
Inhibiteurs de la cholinesterase pour traiter l'inflammation
|
CA2553291A1
(fr)
|
2004-01-29 |
2005-09-09 |
Pfizer Products Inc. |
Combinaison de modulateurs d'acide .gamma.-aminobutyrique et d'antagonistes du recepteur 5-ht1b
|
CA2555172A1
(fr)
|
2004-01-29 |
2005-09-09 |
Pfizer Products Inc. |
Combinaisons d'un antipsychotique atypique et de derives azabicycliques d'aminomethylpyridyloxy- methyle/benzisoxazole pour le traitement de troubles du systeme nerveux central
|
WO2005074535A2
(fr)
|
2004-01-30 |
2005-08-18 |
Eisai Co., Ltd. |
Inhibiteurs de cholinesterase pour des troubles de la colonne vertebrale
|
WO2005080361A1
(fr)
|
2004-02-02 |
2005-09-01 |
Pfizer Products Inc. |
Modulateurs du recepteur de l'histamine-3
|
US20050245460A1
(en)
|
2004-02-13 |
2005-11-03 |
Meyerson Laurence R |
Methods and compositions for the treatment of epilepsy, seizure disorders, and other CNS disorders
|
JP2007522200A
(ja)
|
2004-02-13 |
2007-08-09 |
ファイザー・プロダクツ・インク |
非定型抗精神病薬とコルチコトロピン放出因子拮抗薬の治療的組合せ
|
US20050182044A1
(en)
|
2004-02-17 |
2005-08-18 |
Bruinsma Gosse B. |
Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate
|
EP1720836B1
(fr)
|
2004-02-25 |
2014-04-16 |
Eli Lilly And Company |
2,3,4,5-tetrahydro-1h-benzo [d]azepines substitues en position 6 en tant qu'agonistes de recepteur 5-ht sb 2c /sb
|
GB0405200D0
(en)
|
2004-03-08 |
2004-04-21 |
Pfizer Ltd |
Combinations comprising alpha-2-delta ligands
|
US20060148807A1
(en)
|
2004-03-12 |
2006-07-06 |
Pfizer Inc |
Pyrrolo[1,2b]pyridazine compounds and their uses
|
US20060166998A1
(en)
|
2004-03-12 |
2006-07-27 |
Pfizer Inc |
Pyrrolo[1,2-B]pyridazine compounds and their uses
|
EA200601461A1
(ru)
|
2004-03-17 |
2007-02-27 |
Пфайзер Продактс, Инк. |
Новые производные бензил(иден)лактама
|
WO2005092009A2
(fr)
|
2004-03-19 |
2005-10-06 |
Axonyx, Inc. |
Inhibiteurs d'acetylcholinesterase et antagonistes de n-methyle-d-aspartate utiles dans le traitement de troubles cognitifs
|
WO2005100334A1
(fr)
|
2004-04-14 |
2005-10-27 |
Pfizer Products Inc. |
Inhibiteurs de dipeptidyl peptidase-iv
|
WO2005102272A2
(fr)
|
2004-04-21 |
2005-11-03 |
Pfizer Products Inc. |
Formes posologiques a liberation prolongee de cabergoline
|
US7618978B2
(en)
|
2004-04-22 |
2009-11-17 |
Eli Lilly And Company |
Amides as BACE inhibitors
|
US20050245543A1
(en)
|
2004-04-30 |
2005-11-03 |
Pfizer Inc |
Histamine-3 receptor antagonists
|
JP2007537232A
(ja)
|
2004-05-11 |
2007-12-20 |
ファイザー・プロダクツ・インク |
非定型抗精神病薬と5−ht1b受容体拮抗薬の組合せ
|
JP2008500383A
(ja)
|
2004-05-21 |
2008-01-10 |
ファイザー・プロダクツ・インク |
5−ht1bアンタゴニスト、インバースアゴニストおよび部分アゴニストとしてのテトラヒドロナフチルピペラジン類
|
MXPA06012347A
(es)
|
2004-05-21 |
2007-01-17 |
Pfizer Prod Inc |
Derivados de pirazinilmetil-lactama.
|
US20070212428A1
(en)
*
|
2004-06-04 |
2007-09-13 |
Mood Management Sciences, Inc. |
Methods and compositions for treating mood disorder
|
CA2569411A1
(fr)
|
2004-06-04 |
2005-12-22 |
Mood Management Sciences, Llc |
Compositions et methodes de traitement des troubles de l'humeur
|
CA2568700A1
(fr)
|
2004-06-11 |
2005-12-22 |
Ucb, S.A. |
Processus de preparation de derives 2-oxo-1-pyrrolidine par allylation intramoleculaire
|
MXPA06015267A
(es)
|
2004-06-22 |
2007-03-15 |
Pfizer Prod Inc |
Antagonistas diazabiciclicos del receptor histamina-3.
|
EP1768975A2
(fr)
|
2004-06-25 |
2007-04-04 |
Pfizer Products Inc. |
Pyridyle pipérazines pour le traitement des troubles du snc
|
US7618980B2
(en)
|
2004-07-14 |
2009-11-17 |
Bristol-Myers Squibb Company |
Pyrrolo(oxo)quinolines as 5HT ligands
|
US7572805B2
(en)
|
2004-07-14 |
2009-08-11 |
Bristol-Myers Squibb Company |
Pyrrolo(oxo)isoquinolines as 5HT ligands
|
US20060014733A1
(en)
|
2004-07-19 |
2006-01-19 |
Pfizer Inc |
Histamine-3 agonists and antagonists
|
MX2007000763A
(es)
|
2004-07-21 |
2007-03-28 |
Pfizer Prod Inc |
Antagonistas del receptor 3 de la histamina.
|
EP1789050A1
(fr)
|
2004-08-09 |
2007-05-30 |
Warner-Lambert Company LLC |
Nouveaux inhibiteurs du recaptage de la quinoxaline-norepinephrine pour le traitement de troubles du systeme nerveux central
|
MX2007002136A
(es)
|
2004-09-01 |
2007-04-02 |
Pfizer Prod Inc |
Antagonistas amino azabiciclicos del receptor 3 de la histamina.
|
JP2008512438A
(ja)
|
2004-09-10 |
2008-04-24 |
ファイザー・プロダクツ・インク |
療法用ジフェニルエーテル系リガンド
|
EP1791541A2
(fr)
|
2004-09-10 |
2007-06-06 |
Pfizer Products Inc. |
Procédés de traitement des troubles del'humeur en utilisant des composés diazabicycliques contenant du benzisoxazole
|
WO2006034196A1
(fr)
|
2004-09-17 |
2006-03-30 |
Lifelike Biomatic Inc. |
Compositions pour renforcer la mémoire et procédés idoines
|
US20060069087A1
(en)
|
2004-09-27 |
2006-03-30 |
Pfizer Inc |
Histamine-3 receptor antagonists
|
US9186345B2
(en)
|
2004-10-12 |
2015-11-17 |
Hakon Hakonarson |
Method of treating skin diseases
|
EP1802301A1
(fr)
|
2004-10-15 |
2007-07-04 |
Pfizer Inc. |
Traitement de troubles bipolaires et symptomes associes
|
EP1805160B1
(fr)
|
2004-10-18 |
2011-04-06 |
Eli Lilly And Company |
Benzopyranes substitues utilises comme agonistes selectifs du recepteur d'oestrogenes beta
|
JP5188807B2
(ja)
|
2004-10-18 |
2013-04-24 |
イーライ リリー アンド カンパニー |
mGluR3受容体アンタゴニストとして用いるための1−(ヘテロ)アリール−3−アミノ−ピロリジン誘導体
|
WO2006060082A1
(fr)
|
2004-10-22 |
2006-06-08 |
THE GOVERNMENT OF THE U.S.A. as represented by THE SEC., DEPT. OF HEALTH & HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH |
Composes tricycliques, leur preparation, et leur utilisation comme inhibiteurs de l'activite de la cholinesterase
|
WO2006046131A1
(fr)
|
2004-10-29 |
2006-05-04 |
Pfizer Products Inc. |
Antagonistes vis-a-vis du recepteur d'histamine-3
|
WO2006048727A1
(fr)
|
2004-11-02 |
2006-05-11 |
Pfizer Products Inc. |
Ligands de latame/amine piperazinylphenalkyle pour le recepteur 5ht1b
|
CA2587826A1
(fr)
|
2004-11-15 |
2006-05-18 |
Pfizer Products Inc. |
Azabenzoxazoles pour le traitement des troubles du systeme nerveux central
|
WO2006051394A1
(fr)
|
2004-11-15 |
2006-05-18 |
Pfizer Products Inc. |
Azabenzoxazoles pour traiter des troubles du systeme nerveux central
|
AP2007004024A0
(en)
|
2004-11-29 |
2007-06-30 |
Warner Lambert Co |
Therapeutic pyrazoloÄ3,4-BÜpyridines and indazoles
|
DE602005006840D1
(de)
|
2004-12-07 |
2008-06-26 |
Pfizer Prod Inc |
1,2,3,3a;8,8a-hexahydro-2,7a-diazacyclopentaäaüinden-7-onderivate, die sich an neuronale nikotinische acetylcholinspezifische rezeptorstellen binden und zur modulation der cholinergen funktion und zur behandlung von suchterkrankungen eignen
|
JP2008525439A
(ja)
|
2004-12-23 |
2008-07-17 |
ボイジャー・ファーマシューティカル・コーポレーション |
アルツハイマー病の治療のための酢酸ロイプロリド及びアセチルコリンエステラーゼインヒビターまたはnmdaレセプターアゴニスト
|
EP1831172B1
(fr)
|
2004-12-28 |
2009-02-18 |
Council of Scientific and Industrial Research |
Esters d'acide carbamique quinoline-6-yle substitues utiles en tant qu'inhibiteurs de l'acetylcholinesterase
|
US20060183763A1
(en)
|
2004-12-31 |
2006-08-17 |
Pfizer Inc |
Novel pyrrolidyl derivatives of heteroaromatic compounds
|
US7932249B2
(en)
|
2005-01-05 |
2011-04-26 |
Eli Lilly And Company |
Olanzapine pamoate dihydrate
|
ES2294979T1
(es)
|
2005-01-27 |
2008-04-16 |
Alembic Limited |
Formulacion de levetiracetam de liberacion prolongada.
|
FR2881618B1
(fr)
|
2005-02-10 |
2007-04-13 |
Centre Nat Rech Scient |
Utilisation de composes derives de pyrimidinetrione en tant qu'inhibiteurs de l'acetylcholinesterase, compositions contenant ces derives et leurs utilisations en tant qu'insecticides
|
US7238702B2
(en)
|
2005-02-10 |
2007-07-03 |
Bristol-Myers Squibb Company |
Dihydroquinazolinones as 5HT modulators
|
US8093302B2
(en)
|
2005-02-15 |
2012-01-10 |
Eli Lilly And Company |
Substituted tetralins as selective estrogen receptor-β agonists
|
US20070298098A1
(en)
|
2005-02-16 |
2007-12-27 |
Elan Pharma International Limited |
Controlled Release Compositions Comprising Levetiracetam
|
ES2403069T3
(es)
|
2005-02-22 |
2013-05-13 |
Sun Pharma Advanced Research Company Ltd |
Composición oral de liberación controlada que contiene levetiracetam
|
WO2006090272A1
(fr)
|
2005-02-22 |
2006-08-31 |
Warner-Lambert Company Llc |
Isoquinoline [1,8]naphthyridin-2-ones et composes relatifs destines au traitement de la schizophrenie
|
WO2006090273A2
(fr)
|
2005-02-22 |
2006-08-31 |
Warner-Lambert Company Llc |
[1,8]naphthyridin-2-ones et composes relatifs a liants ceto ou hydroxyl destines au traitement de la schizophrenie
|
AU2006228947A1
(en)
|
2005-03-30 |
2006-10-05 |
Mylan Pharmaceuticals Ulc |
Combined-step process for pharmaceutical compositions
|
BRPI0607918A2
(pt)
|
2005-04-01 |
2009-10-20 |
Warner Lambert Co |
tetraidro-piridoazepin-8-onas e compostos relacionados para o tratemento da esquizofrenia.
|
DE602006016934D1
(de)
|
2005-04-06 |
2010-10-28 |
Adamas Pharmaceuticals Inc |
Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
|
JP4193949B2
(ja)
|
2005-04-08 |
2008-12-10 |
ファイザー・プロダクツ・インク |
I型グリシン輸送阻害剤としての二環式[3.1.0]ヘテロアリールアミド
|
WO2006106416A1
(fr)
|
2005-04-08 |
2006-10-12 |
Pfizer Products Inc. |
Pyridil-lactams et leur utilisation comme ligands de recepteurs 5-ht1
|
US20080305161A1
(en)
|
2005-04-13 |
2008-12-11 |
Pfizer Inc |
Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
|
US7741358B2
(en)
|
2005-04-14 |
2010-06-22 |
N.V. Organon |
Crystal form of asenapine maleate
|
US20060241144A1
(en)
|
2005-04-20 |
2006-10-26 |
Albert Cha |
Method for treating apathy syndrome
|
US7456188B1
(en)
|
2005-04-28 |
2008-11-25 |
Bristol-Myers Squibb Company |
C-5 substituted quinazolinone derivatives as selective estrogen receptor beta modulators
|
US20060276412A1
(en)
*
|
2005-05-31 |
2006-12-07 |
Gary Tollefson |
Methods and compositions for managing psychotic disorders
|
AU2006254335A1
(en)
|
2005-06-01 |
2006-12-07 |
Ucb Pharma, S.A. |
2-oxo-1-pyrrolidine derivatives and their therapeutic use on the central nervous system
|
EP1731149A1
(fr)
|
2005-06-08 |
2006-12-13 |
Ucb S.A. |
Utilisation de Brivaracetam pour le traitement de maladies caracterisées par l'épilepsie myoclonique progressive
|
EP1899296B1
(fr)
|
2005-06-22 |
2010-11-17 |
Pfizer Products Inc. |
Antagonistes du recepteur 3 de l'histamine
|
US20070015763A1
(en)
|
2005-07-12 |
2007-01-18 |
Pfizer Inc |
Treatment of psychosis associated with parkinson's disease and subcortical dementias using a combination of an atypical antipsychotic with a dopamine agonist
|
CA2617102A1
(fr)
|
2005-07-28 |
2007-02-08 |
Bristol-Myers Squibb Company |
Tetrahydro-1h-pyrido[4,3,b]indoles substitues utilises en tant qu'agonistes et antagonistes des recepteurs de la serotonine
|
WO2007019312A2
(fr)
|
2005-08-03 |
2007-02-15 |
The Johns Hopkins University |
Methodes permettant de caracteriser et de traiter un trouble cognitif du au vieillissement ou une maladie
|
WO2007017750A1
(fr)
|
2005-08-08 |
2007-02-15 |
Pfizer Products Inc. |
Sel de benzoate de 4-(5-methyl-oxazolo[4,5-b]pyridin-2-yl)-1,4-diaza-bicyclo[3.2.2]nonane
|
US7795436B2
(en)
|
2005-08-24 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
|
GB0517740D0
(en)
|
2005-08-31 |
2005-10-12 |
Novartis Ag |
Organic compounds
|
WO2007026219A2
(fr)
|
2005-08-31 |
2007-03-08 |
Pfizer Products Inc. |
Composition d'antagonistes du recepteur 5-ht1b servant au traitement d'etats du systeme nerveux central
|
SI1924561T1
(sl)
|
2005-09-01 |
2013-02-28 |
Eli Lilly And Company |
6-arilalkilamino-2,3,4,5-tetrahidro-1h-benzo(d)azepini kot agonisti 5-ht2c receptorja
|
CN101253153A
(zh)
|
2005-09-01 |
2008-08-27 |
伊莱利利公司 |
作为5-HT<sub>2c</sub>受体激动剂的6-取代的2,3,4,5-四氢-1H-苯并[d]氮杂䓬
|
CA2619450C
(fr)
|
2005-09-01 |
2013-10-22 |
Eli Lilly And Company |
2,3,4,5-tetrahydro-1h-benzo[d]azepines substituees par un heterocycle a liaison 6-n en tant qu'agonistes de recepteur 5-ht2c
|
EP1924560B1
(fr)
|
2005-09-01 |
2009-08-05 |
Eli Lilly And Company |
2,3,4,5-tetrahydro-1h-benzo[d]azepines 6-substituees en tant qu'antagonistes du recepteur 5-ht2c
|
US20090215857A1
(en)
|
2005-09-13 |
2009-08-27 |
Pfizer Products Inc. |
Therapeutic Pyrrolidines
|
US7745447B2
(en)
|
2005-10-26 |
2010-06-29 |
Bristol-Myers Squibb Company |
Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists
|
US8618115B2
(en)
|
2005-10-26 |
2013-12-31 |
Bristol-Myers Squibb Company |
Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
|
US8158673B2
(en)
|
2005-10-27 |
2012-04-17 |
Pfizer Inc. |
Histamine-3 receptor antagonists
|
WO2007057742A2
(fr)
|
2005-11-18 |
2007-05-24 |
Pfizer Products Inc. |
Nouveaux derives de piperazinone
|
WO2007063385A2
(fr)
|
2005-12-01 |
2007-06-07 |
Pfizer Products Inc. |
Antagonistes des recepteurs de l'histamine 3 pour des amines spirocycliques
|
WO2007065595A2
(fr)
|
2005-12-07 |
2007-06-14 |
Ucb Pharma, S.A. |
Derives de la xanthine, procedes de preparation et utilisations de ceux-ci
|
WO2007069053A1
(fr)
|
2005-12-14 |
2007-06-21 |
Pfizer Products Inc. |
Antagonistes benzimidazoliques du récepteur h-3
|
NL2000397C2
(nl)
|
2006-01-05 |
2007-10-30 |
Pfizer Prod Inc |
Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
|
JP2009524637A
(ja)
|
2006-01-27 |
2009-07-02 |
ファイザー・プロダクツ・インク |
アミノフタラジン誘導体化合物
|
WO2007088462A1
(fr)
|
2006-02-01 |
2007-08-09 |
Pfizer Products Inc. |
Antagonistes du récepteur du h-3 à base de spirochromane
|
WO2007088450A2
(fr)
|
2006-02-01 |
2007-08-09 |
Pfizer Products Inc. |
Chromane antagoniste du récepteur h-3
|
US7553836B2
(en)
|
2006-02-06 |
2009-06-30 |
Bristol-Myers Squibb Company |
Melanin concentrating hormone receptor-1 antagonists
|
CA2641670A1
(fr)
|
2006-02-23 |
2007-08-30 |
Pfizer Products Inc. |
Quinazolines substituees en tant qu'inhibiteurs de pde10
|
WO2007099423A1
(fr)
|
2006-03-02 |
2007-09-07 |
Pfizer Products Inc. |
Dérivés de 1-pyrrolidine indane en tant qu'antagonistes du récepteur d'histamine 3
|
US20100216734A1
(en)
*
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
AU2007223036A1
(en)
|
2006-03-08 |
2007-09-13 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
EP2007749A2
(fr)
|
2006-03-13 |
2008-12-31 |
Pfizer Products Inc. |
Tétralines en tant qu'antagonistes du récepteur h-3
|
WO2007107846A1
(fr)
|
2006-03-20 |
2007-09-27 |
Council Of Scientific And Industrial Research |
Composition pharmaceutique utile en tant qu'inhibiteur de l'acétyl cholinestérase
|
US20070224636A1
(en)
|
2006-03-24 |
2007-09-27 |
Pfizer Inc |
Pyrrolo[1,2b]pyridazine compounds and their uses
|
WO2007127474A2
(fr)
|
2006-04-28 |
2007-11-08 |
Northwestern University |
Compositions et traitements utilisant des pyridazines et des inhibiteurs de cholinestérase
|
CA2650976A1
(fr)
|
2006-05-02 |
2007-11-15 |
Pfizer Products Inc. |
Composes d'heteroaryle bicyclique utilises comme inhibiteurs de la pde10
|
WO2007134077A2
(fr)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
Neurogenèse induite par le récepteur 5ht
|
US7858611B2
(en)
|
2006-05-09 |
2010-12-28 |
Braincells Inc. |
Neurogenesis by modulating angiotensin
|
WO2007138431A2
(fr)
|
2006-05-30 |
2007-12-06 |
Pfizer Products Inc. |
Antagonistes de l'éther histamine-3 azabicyclique
|
BRPI0712325A2
(pt)
|
2006-06-08 |
2012-01-10 |
Ucb Pharma Sa |
processo para a preparação de co-cristais de pirrolidinonas, co-cristal, composição farmacêutica, e, uso de um co-cristal
|
WO2008001182A1
(fr)
|
2006-06-26 |
2008-01-03 |
Pfizer Products Inc. |
Composés hétéroaryliques tricycliques comme inhibiteurs de pde10
|
US20080014271A1
(en)
|
2006-07-13 |
2008-01-17 |
Ucb, S.A. |
Novel pharmaceutical compositions comprising levetiracetam
|
DE602007012254D1
(de)
|
2006-07-14 |
2011-03-10 |
Pfizer Prod Inc |
Tartratsalz von (7s)-7-ä(5-fluor-2-methylbenzyl)oxyü-2-ä(2r)-2-methylpiperazin-1-ylü-6,7-dihydro-5h-cyclopentaäbüpyridin
|
WO2008015516A1
(fr)
|
2006-07-28 |
2008-02-07 |
Pfizer Products Inc. |
Hétérocycles tricycliques à cycles fusionnés dans le traitement de la schizophrénie
|
US20080045512A1
(en)
|
2006-08-09 |
2008-02-21 |
Pfizer Inc. |
Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]-pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane
|
WO2008020302A2
(fr)
|
2006-08-17 |
2008-02-21 |
Pfizer Products Inc. |
Composés hétéro-aromatiques à base de quinoline
|
WO2008020306A2
(fr)
|
2006-08-18 |
2008-02-21 |
Pfizer Products Inc. |
Dérivés d'isoindole
|
EP2051696A2
(fr)
|
2006-08-18 |
2009-04-29 |
Morton Grove Pharmaceuticals, Inc. |
Compositions liquides stables de lévétiracétam et procédés
|
WO2008026046A1
(fr)
|
2006-08-30 |
2008-03-06 |
Pfizer Products Inc. |
Antagonistes à base de morpholine de la dopamine d3
|
EP2114897A2
(fr)
|
2006-09-12 |
2009-11-11 |
Pfizer Products Inc. |
Dérivés de benzimidazolone
|
WO2008062446A2
(fr)
|
2006-09-14 |
2008-05-29 |
Alembic Limited |
Composition de lévétiracétam à libération prolongée n'impliquant pas d'effets indésirables en présence d'aliments
|
AU2007299726A1
(en)
|
2006-09-22 |
2008-03-27 |
Braincells, Inc. |
Combination comprising an HMG-COA reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
|
AR063497A1
(es)
|
2006-10-23 |
2009-01-28 |
Lilly Co Eli |
Compuesto de pirrodinil -2-ona, intermediario para la sintesis del mismo, composicion farmaceutica que lo comprende y su uso para preparar un medicamento
|
US20100152108A1
(en)
|
2006-10-27 |
2010-06-17 |
Medivation Neurology, Inc. |
Methods and combination therapies for treating alzheimer's disease
|
WO2008065500A2
(fr)
|
2006-11-30 |
2008-06-05 |
Pfizer Products Inc. |
Hétéroaryl amides comme inhibiteurs du transport de la glycine de type i
|
US8247563B2
(en)
|
2006-12-11 |
2012-08-21 |
Reviva Pharmaceuticals, Inc. |
Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors
|
WO2008074896A1
(fr)
|
2006-12-21 |
2008-06-26 |
Prendergast Patrick T |
Compositions et procédés de traitement de troubles neurologiques chroniques
|
WO2008084324A1
(fr)
|
2007-01-04 |
2008-07-17 |
Pfizer Products Inc. |
Composé de naphtyridinone
|
ES2395744T3
(es)
|
2007-01-22 |
2013-02-14 |
Pfizer Products Inc. |
Sal de tosilato de un compuesto terapéutico y sus composiciones farmacéuticas
|
JP2010518010A
(ja)
|
2007-02-02 |
2010-05-27 |
コルシド・ファーマシューティカルズ・インコーポレイテッド |
コリンエステラーゼを阻害する化合物
|
FR2912056B1
(fr)
|
2007-02-05 |
2009-12-18 |
Rd Pharmagal |
Composition a liberation prolongee de levetiracetam et procede de preparation
|
KR101060892B1
(ko)
|
2007-02-07 |
2011-08-31 |
화이자 인코포레이티드 |
Pkc 억제제로서의 3-아미노-피롤로[3,4-c] 피라졸-5(1h,4h,6h) 카브알데하이드 유도체
|
AU2007346591A1
(en)
|
2007-02-07 |
2008-08-14 |
Gosforth Centre (Holdings) Pty Ltd |
Treatment of ADHD
|
AU2008237660B2
(en)
|
2007-04-12 |
2011-12-22 |
Pfizer Inc. |
3-amido-pyrrolo [3, 4-C] pyrazole-5 (1H, 4H, 6H) carbaldehyde derivatives as inhibitors of protein kinase C
|
CN101687882A
(zh)
|
2007-04-25 |
2010-03-31 |
百时美施贵宝公司 |
非碱性黑色素浓集激素受体-1拮抗剂
|
WO2008132142A2
(fr)
|
2007-04-27 |
2008-11-06 |
Ucb Pharma S.A. |
Nouveaux dérivés hétérocycliques utiles pour le traitement des troubles du système nerveux central
|
US7846930B2
(en)
|
2007-05-18 |
2010-12-07 |
Janssen Pharmaceutica Nv |
Diaryl-substituted tetrahydroisoquinolines as histamine H3 receptor and serotonin transporter modulators
|
US20090011994A1
(en)
|
2007-07-06 |
2009-01-08 |
Bristol-Myers Squibb Company |
Non-basic melanin concentrating hormone receptor-1 antagonists and methods
|
RU2339620C1
(ru)
|
2007-07-09 |
2008-11-27 |
Общество С Ограниченной Ответственностью "Фармвинг" |
Оксалат n, n-диметил-2-n, n-диметиламинометилпиридил-3-карбамат, обладающий антихолинэстеразной активностью и способностью улучшать когнитивные функции
|
EP2164489A2
(fr)
|
2007-07-13 |
2010-03-24 |
Eisai R&D Management Co., Ltd. |
Anatagonistes des récepteurs ampa contre la douleur neuropathique
|
US20090030403A1
(en)
|
2007-07-27 |
2009-01-29 |
Leyde Kent W |
Methods and Systems for Attenuating the Tolerance Response to a Drug
|
WO2009038412A2
(fr)
|
2007-09-21 |
2009-03-26 |
Lg Life Sciences, Ltd. |
Composés inhibiteurs de la béta-sécrétase
|
US20090176740A1
(en)
|
2007-11-30 |
2009-07-09 |
Phillips Ii Dauglas James |
Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine
|
MX2010006162A
(es)
|
2007-12-07 |
2010-06-25 |
Pfizer |
Sal tosilato de una trans-n-isobutil-3-fluoro-3-[3-fluoro-4-(pirro lidin-1-il-metil)fenil]ciclobutanocarboxamida.
|
US20100297181A1
(en)
*
|
2007-12-26 |
2010-11-25 |
Eisai R&D Management Co., Ltd. |
AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ
|
CA2713025C
(fr)
|
2008-01-22 |
2012-12-04 |
Eli Lilly And Company |
Antagoniste selectif des recepteurs d'opioides kappa
|
WO2009098576A1
(fr)
|
2008-02-05 |
2009-08-13 |
Pfizer Inc. |
Pyridinylamides pour le traitement des troubles du snc et du métabolisme
|
AU2009221177B2
(en)
|
2008-03-03 |
2013-05-30 |
Ucb Biopharma Sprl |
Pharmaceutical solutions, process of preparation and therapeutic uses
|
JP2011518143A
(ja)
|
2008-04-17 |
2011-06-23 |
ファイザー・インク |
Faah阻害剤として有用なエーテルベンジリデンピペリジンアリールカルボキサミド化合物
|
JP5539322B2
(ja)
|
2008-04-22 |
2014-07-02 |
イーライ リリー アンド カンパニー |
Cb−1リガンドとしての1,5−ジフェニル−ピロリジン−2−オン化合物
|
JP5539323B2
(ja)
|
2008-04-22 |
2014-07-02 |
イーライ リリー アンド カンパニー |
Cb−1リガンドとしての1,5−ジフェニル−ピロリジン−2−オン化合物
|
AR071997A1
(es)
|
2008-06-04 |
2010-07-28 |
Bristol Myers Squibb Co |
Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
|
US20110212944A1
(en)
|
2008-07-01 |
2011-09-01 |
Julie Liu |
2-oxo-1-pyrrolidine derivatives
|
JP2010024156A
(ja)
|
2008-07-16 |
2010-02-04 |
Ucb Pharma Sa |
レベチラセタムを含む医薬組成物
|
TW201006801A
(en)
|
2008-07-18 |
2010-02-16 |
Lilly Co Eli |
Imidazole carboxamides
|
US7932256B2
(en)
|
2008-07-31 |
2011-04-26 |
Bristol-Myers Squibb Company |
(S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity
|
AU2009279372A1
(en)
|
2008-08-06 |
2010-02-11 |
Gosforth Centre (Holdings) Pty Ltd |
Compositions and methods for treating psychiatric disorders
|
DK3260118T3
(da)
|
2008-10-16 |
2021-04-19 |
Univ Johns Hopkins |
Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion
|
US20100113465A1
(en)
|
2008-10-30 |
2010-05-06 |
Pfizer Inc. |
7-azaspiro[3.5]nonane-7-carboxamide compounds
|
US9125898B2
(en)
|
2008-11-14 |
2015-09-08 |
Neurotune Ag |
Acetam derivatives for pain relief
|
WO2010057088A2
(fr)
|
2008-11-17 |
2010-05-20 |
Auspex Pharmaceuticals, Inc. |
Modulateurs de pyrrolidinyle de récepteurs nicotiniques d'acétylcholine
|
PT2358360T
(pt)
|
2008-11-18 |
2016-11-15 |
Ucb Biopharma Sprl |
Formulações de libertação prolongada compreendendo um derivado de 2-oxo-1-pirrolidina
|
CA2741839A1
(fr)
|
2008-11-21 |
2010-05-27 |
Pfizer Inc. |
1-oxa-8-azaspiro[4.5]decane-8-carboxamides en tant qu'inhibiteurs de faah
|
US20100172979A1
(en)
|
2008-12-24 |
2010-07-08 |
Zhongshui Yu |
Controlled-release formulations
|
KR101665001B1
(ko)
|
2009-01-29 |
2016-10-11 |
유씨비 파마, 에스.에이. |
2옥소1피롤리딘 유도체를 포함하는 약학적 조성물
|
EP2393483B1
(fr)
|
2009-02-09 |
2017-06-28 |
UCB Biopharma SPRL |
Compositions pharmaceutiques comportant du brivaracetam
|
US8563583B2
(en)
|
2009-03-09 |
2013-10-22 |
Bristol-Myers Squibb Company |
Pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
|
US8278316B2
(en)
|
2009-03-09 |
2012-10-02 |
Bristol-Myers Squibb Company |
Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
|
WO2010111080A2
(fr)
|
2009-03-27 |
2010-09-30 |
Eli Lilly And Company |
Traitement optimisé de la schizophrénie
|
US8846411B2
(en)
|
2009-06-11 |
2014-09-30 |
Microgenics Corporation |
Derivatives, reagents, and immunoassay for detecting levetiracetam
|
CA2763960C
(fr)
|
2009-06-18 |
2014-07-08 |
Pfizer Inc. |
Composes bicycliques et tricycliques utilises en tant qu'inhibiteurs de kat ii
|
EP2461808A2
(fr)
|
2009-08-07 |
2012-06-13 |
UCB Pharma S.A. |
Procédés pour améliorer la fonction cognitive
|
CN101647789B
(zh)
|
2009-09-01 |
2011-08-17 |
天津药物研究院药业有限责任公司 |
左乙拉西坦缓释微丸胶囊制剂
|
CN102548544B
(zh)
|
2009-10-09 |
2015-01-21 |
永进药品工业株式会社 |
同时具有速效特性和长效特性的药物组合物
|
US20110262442A1
(en)
*
|
2009-11-06 |
2011-10-27 |
Adenios, Inc. |
Compositions for treating cns disorders
|
UA107943C2
(en)
|
2009-11-16 |
2015-03-10 |
Lilly Co Eli |
Compounds of spiropiperidines as antagonists of the orl-1 receptors
|
CA2781041C
(fr)
|
2009-11-16 |
2015-01-06 |
Eli Lilly And Company |
Composes de spiropiperidine en tant qu'antagonistes de recepteur orl-1
|
JO2978B1
(en)
|
2009-12-21 |
2016-03-15 |
ايلي ليلي اند كومباني |
MGLU2 aids
|
JP6082250B2
(ja)
|
2010-02-09 |
2017-02-15 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
認知機能を改善するための方法および組成物
|
WO2011143721A1
(fr)
|
2010-05-21 |
2011-11-24 |
Gosforth Centre (Holdings) Pty Ltd |
Compositions et procédés pour le traitement de troubles neurodégénératifs
|
US8883812B2
(en)
|
2010-07-08 |
2014-11-11 |
Pfizer Inc. |
Piperidinyl pyrimidine amides as Kv7 potassium channel openers
|
JP2013540752A
(ja)
|
2010-09-21 |
2013-11-07 |
ファイザー・インク |
カリウムチャネル関連疾患の治療のためのピリミドン
|
US20140030343A1
(en)
|
2010-10-26 |
2014-01-30 |
Alpharma Pharmaceuticals Llc |
Formulations and Methods for Attenuating Respiratory Depression Induced by Opioid Overdose
|
KR20120055313A
(ko)
|
2010-11-23 |
2012-05-31 |
주식회사 바이오파마티스 |
레베티라세탐 또는 이의 약학적으로 허용되는 염을 포함하는 용출 안정성이 개선된 서방형 약학 조성물 및 이의 제조방법
|
KR101544290B1
(ko)
|
2010-12-01 |
2015-08-12 |
화이자 인코포레이티드 |
Kat ii 억제제
|
AU2011336217B2
(en)
|
2010-12-01 |
2015-10-01 |
Pfizer Inc. |
KAT II inhibitors
|
AU2012214303A1
(en)
*
|
2011-02-09 |
2013-09-12 |
The Johns Hopkins University |
Methods and compositions for improving cognitive function
|
JP5543039B2
(ja)
|
2011-02-23 |
2014-07-09 |
ファイザー・インク |
神経障害治療のためのイミダゾ[5,1−f][1,2,4]トリアジン
|
DE102011103270A1
(de)
|
2011-05-26 |
2012-11-29 |
Stada Arzneimittel Ag |
Pulverförmige Mischung zur Herstellung von Levetiracetam-haltigen Tabletten
|
GB201111712D0
(en)
|
2011-07-08 |
2011-08-24 |
Gosforth Ct Holdings Pty Ltd |
Pharmaceutical compositions
|
CA2891122C
(fr)
|
2012-11-14 |
2021-07-20 |
The Johns Hopkins University |
Methodes et compositions pour le traitement de la schizophrenie
|
WO2014144663A1
(fr)
|
2013-03-15 |
2014-09-18 |
The Johns Hopkins University |
Procédés et compositions pour améliorer la fonction cognitive
|
CN105142623A
(zh)
|
2013-03-15 |
2015-12-09 |
艾吉因生物股份有限公司 |
用于改善认知功能的方法和组合物
|
WO2014144546A1
(fr)
|
2013-03-15 |
2014-09-18 |
The Johns Hopkins University |
Procédés et compositions pour améliorer la fonction cognitive
|
NZ738682A
(en)
|
2015-05-22 |
2022-01-28 |
Agenebio Inc |
Extended release pharmaceutical compositions of levetiracetam
|